What Schools Are Affiliated With Gordon B. Mills

Gordon B. Mills is affiliated with the following schools: University of Toronto, Duke University, Stockholm University, University of Trieste, McGill University, Sam Houston State University, National Cheng Kung University, Imperial College London, Ohio State University, University of Ottawa, University of British Columbia, Chinese University of Hong Kong, University of South Florida, China Medical University , Oregon Health & Science University, University of Pittsburgh, University of Zurich, University of Texas Southwestern Medical Center, Harvard University, University of Western Ontario, University of Oslo, Medical University of Vienna, University of Kentucky, MD Anderson Cancer Center, University of Tokyo, University of Alberta

Gordon B. Mills | Academic Influence

Gordon B. Mills's AcademicInfluence.com Rankings

Gordon B. Mills

Medical

#438

World Rank

#603

Historical Rank

Oncology

#13

World Rank

#14

Historical Rank

medical Degrees

Gordon B. Mills

Law

#927

World Rank

#1201

Historical Rank

Common Law

World Rank

Historical Rank

International Law

#73

World Rank

#110

Historical Rank

law Degrees

Download Badge

Medical
Law

Why Is Gordon B. Mills Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Gordon B. Mills is the Wayne and Julie Drinkward Endowed Chair in Precision Oncology, Director of Precision Oncology, Director of SMMART Trials and Professor in Cell, Development and Cancer Biology in the Knight Cancer Institute at Oregon Health & Science University.

(See a Problem?)

Gordon B. Mills's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comprehensive molecular portraits of human breast tumors (2012) (7791)
Integrated Genomic Analyses of Ovarian Carcinoma (2011) (6411)
The Cancer Genome Atlas Pan-Cancer analysis project (2013) (5479)
Comprehensive molecular characterization of gastric adenocarcinoma (2014) (4496)
Comprehensive molecular characterization of gastric adenocarcinoma (2014) (4496)
Inferring tumour purity and stromal and immune cell admixture from expression data (2013) (4215)
Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
Integrated genomic characterization of endometrial carcinoma (2013) (3708)
The Somatic Genomic Landscape of Glioblastoma (2013) (3693)
Use of proteomic patterns in serum to identify ovarian cancer (2002) (3136)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (2012) (2913)
Comprehensive genomic characterization of head and neck squamous cell carcinomas (2015) (2860)
The Immune Landscape of Cancer (2018) (2766)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. (2006) (2509)
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. (2015) (2211)
Genomic Classification of Cutaneous Melanoma (2015) (2143)
The Molecular Taxonomy of Primary Prostate Cancer (2015) (2116)
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery (2005) (2014)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) (2007)
Comprehensive molecular characterization of urothelial bladder carcinoma (2014) (1748)
Comprehensive molecular characterization of clear cell renal cell carcinoma (2013) (1724)
Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth (2011) (1638)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. (2007) (1584)
Next-generation characterization of the Cancer Cell Line Encyclopedia (2019) (1561)
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma (2017) (1514)
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma (2016) (1474)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2017) (1446)
Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer (2009) (1432)
Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response (2018) (1427)
Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer (2015) (1332)
The biology of ovarian cancer: new opportunities for translation (2009) (1317)
Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling (2012) (1283)
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 (2008) (1262)
PIK3CA is implicated as an oncogene in ovarian cancer (1999) (1203)
Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin (2014) (1192)
Rethinking ovarian cancer: recommendations for improving outcomes (2011) (1148)
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. (2017) (1092)
The emerging role of lysophosphatidic acid in cancer (2003) (1062)
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. (2008) (993)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. (2016) (931)
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production (2002) (892)
The energy sensing LKB1–AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis (2007) (850)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer (2014) (850)
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. (2009) (829)
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas (2016) (826)
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance (2012) (799)
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. (2000) (770)
Integrated genomic and molecular characterization of cervical cancer (2017) (762)
Phosphorylation of β-Catenin by AKT Promotes β-Catenin Transcriptional Activity* (2007) (725)
Derailed endocytosis: an emerging feature of cancer (2008) (700)
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells (2006) (661)
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation (2008) (653)
ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS (2010) (631)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016) (604)
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. (2015) (601)
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas (2018) (600)
State-of-the-art strategies for targeting the DNA damage response in cancer (2018) (590)
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. (2015) (550)
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. (2013) (543)
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. (2005) (543)
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers (2004) (521)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer (2011) (520)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer (2012) (515)
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. (2013) (515)
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. (2009) (510)
Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. (1997) (492)
A module of negative feedback regulators defines growth factor signaling (2007) (486)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (480)
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. (2006) (476)
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors (2003) (473)
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC (1998) (462)
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. (2010) (459)
Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis (2004) (445)
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells (2003) (444)
Subtype and pathway specific responses to anticancer compounds in breast cancer (2011) (439)
A pan-cancer proteomic perspective on The Cancer Genome Atlas (2014) (437)
PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells (2013) (430)
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. (2011) (415)
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. (2008) (414)
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. (2012) (411)
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. (2002) (396)
Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. (2013) (389)
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. (2018) (381)
TCPA: a resource for cancer functional proteomics data (2013) (381)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. (2013) (374)
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. (2009) (372)
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. (2017) (371)
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. (2009) (364)
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. (2012) (362)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. (2017) (361)
A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. (2014) (359)
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. (2015) (357)
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. (2010) (355)
Rab25 associates with α5β1 integrin to promote invasive migration in 3D microenvironments (2007) (351)
Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer (2007) (350)
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance (2016) (350)
Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. (2013) (347)
Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells* (2003) (347)
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. (2015) (342)
XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. (2001) (341)
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer (2010) (340)
Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (340)
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications (2014) (336)
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis (2006) (321)
The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells (1999) (319)
Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells (2004) (316)
In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). (2000) (314)
Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma* (2005) (311)
NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. (1999) (311)
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. (2008) (310)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. (2015) (310)
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition (2012) (307)
PARPi triggers STING-dependent immune response and enhances therapeutic efficacy of immune checkpoint blockade independent of BRCAness (2018) (307)
Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon (2005) (299)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade (2018) (297)
Determinants of Rapamycin Sensitivity in Breast Cancer Cells (2004) (294)
Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels* (2014) (292)
Lysophosphatidic acid is a bioactive mediator in ovarian cancer. (2002) (291)
Multiplex digital spatial profiling of proteins and RNA in fixed tissue (2020) (291)
Lysophospholipids activate ovarian and breast cancer cells. (1995) (291)
A Genetically Defined Model for Human Ovarian Cancer (2004) (288)
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers (2008) (284)
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. (2016) (284)
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. (2009) (282)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer (2018) (277)
Identification of the tyrosine phosphatase PTP1C as a B cell antigen receptor-associated protein involved in the regulation of B cell signaling (1995) (277)
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. (2018) (276)
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway (1999) (276)
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. (2008) (274)
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward (2006) (272)
Integrated Molecular Characterization of Uterine Carcinosarcoma. (2017) (271)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors (2014) (271)
HLA-G expression during preimplantation human embryo development. (1996) (268)
The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. (2017) (267)
Modeling precision treatment of breast cancer (2013) (265)
A novel AKT3 mutation in melanoma tumours and cell lines (2008) (263)
Assessing the clinical utility of cancer genomic and proteomic data across tumor types (2014) (262)
Future of personalized medicine in oncology: a systems biology approach. (2010) (259)
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. (2005) (258)
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents (2012) (255)
Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. (2001) (254)
Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. (1995) (253)
Tyrosine Phosphorylation of p85 Relieves Its Inhibitory Activity on Phosphatidylinositol 3-Kinase* (2001) (253)
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer (2009) (253)
Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites (1999) (251)
Lysophospholipid Growth Factors in the Initiation, Progression, Metastases, and Management of Ovarian Cancer (2000) (250)
Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils (1996) (249)
A new mutational AKTivation in the PI3K pathway. (2007) (245)
Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. (1998) (244)
CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line. (1994) (244)
Functional proteomic profiling of AML predicts response and survival. (2009) (243)
Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades* (2003) (243)
ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. (2011) (242)
Targeting the hepatocyte growth factor-cMET axis in cancer therapy. (2012) (241)
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer (2010) (240)
The PI3K/AKT Pathway and Renal Cell Carcinoma. (2015) (240)
Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. (2002) (238)
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma (2009) (234)
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution (2020) (234)
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics (2018) (234)
Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. (2003) (232)
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. (2001) (232)
Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models (2011) (231)
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer (2012) (230)
Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. (2010) (230)
Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. (2007) (229)
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance (2012) (228)
AMPK: a contextual oncogene or tumor suppressor? (2013) (227)
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer (2018) (225)
Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. (2003) (225)
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers (2010) (224)
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer (2011) (222)
CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. (1996) (216)
Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients. (2016) (212)
Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. (2010) (212)
Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency (2007) (209)
Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. (2008) (209)
Emerging role of RAB GTPases in cancer and human disease. (2005) (208)
Genetic analysis of early- versus late-stage ovarian tumors. (2001) (208)
Non-parametric quantification of protein lysate arrays (2007) (205)
Inferring causal molecular networks: empirical assessment through a community-based effort (2016) (205)
Vimentin is a novel AKT1 target mediating motility and invasion (2010) (203)
Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. (2011) (203)
Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling (2002) (201)
Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype (2018) (198)
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors (2012) (198)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells* (2004) (197)
Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer (2009) (196)
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. (2016) (195)
Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. (2014) (194)
Rak functions as a tumor suppressor by regulating PTEN protein stability and function. (2009) (191)
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
Convergence of Multiple Signaling Cascades at Glycogen Synthase Kinase 3: Edg Receptor-Mediated Phosphorylation and Inactivation by Lysophosphatidic Acid through a Protein Kinase C-Dependent Intracellular Pathway (2002) (184)
Uniparental disomy in cancer. (2009) (183)
Genome-wide Transcriptome Profiling of Homologous Recombination DNA Repair (2014) (182)
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. (2007) (180)
Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. (2016) (180)
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. (2003) (179)
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates (2009) (178)
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas (2017) (178)
Src Kinase Activity Is Regulated by the SHP-1 Protein-tyrosine Phosphatase* (1997) (177)
Lineage Infidelity of MDA-MB-435 Cells (2004) (177)
Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition (1997) (176)
Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. (2009) (176)
CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence (2017) (175)
Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. (2000) (175)
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. (2018) (173)
SHP-1 Regulates Lck-induced Phosphatidylinositol 3-Kinase Phosphorylation and Activity* (1999) (172)
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias (2004) (171)
Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer (2013) (169)
Systematic Functional Annotation of Somatic Mutations in Cancer. (2018) (169)
A decision support framework for genomically informed investigational cancer therapy. (2015) (168)
Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. (2017) (166)
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and -independent mechanisms (2011) (166)
Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. (2009) (165)
Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotic cell death. (1993) (164)
Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. (2010) (163)
Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. (2014) (163)
Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. (2015) (161)
Mammalian target of rapamycin. (2004) (161)
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. (2006) (160)
CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis (2010) (160)
Cancer Systems Biology: a peek into the future of patient care? (2014) (159)
Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. (1999) (159)
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. (2011) (159)
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer (2016) (159)
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer (2012) (158)
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers (2017) (158)
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. (2007) (156)
The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. (2003) (155)
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours (2015) (154)
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. (2011) (154)
Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells (2010) (153)
Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. (1995) (152)
Carba Analogs of Cyclic Phosphatidic Acid Are Selective Inhibitors of Autotaxin and Cancer Cell Invasion and Metastasis* (2006) (152)
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. (2014) (152)
Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. (1993) (152)
Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells (2013) (151)
Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. (2018) (151)
Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells (2007) (150)
Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. (1990) (149)
Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. (2006) (149)
Elevated levels and altered fatty acid composition of plasma lysophosphatidlycholine(lysoPC) in ovarian cancer patients (1997) (147)
Clinical Assessment of PTEN Loss in Endometrial Carcinoma: Immunohistochemistry Out-Performs Gene Sequencing (2011) (144)
The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. (2018) (143)
Increase in cytosolic free calcium concentration is an intracellular messenger for the production of interleukin 2 but not for expression of the interleukin 2 receptor. (1985) (143)
G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. (2006) (142)
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. (2019) (141)
Autotaxin/Lysopholipase D and Lysophosphatidic Acid Regulate Murine Hemostasis and Thrombosis* (2009) (140)
Proliferation of murine thymic lymphocytes in vitro is mediated by the concanavalin A-induced release of a lymphokine (costimulator). (1976) (140)
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. (2010) (140)
Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo (2001) (140)
Early detection of ovarian cancer: promise and reality. (2002) (139)
α-Tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. (2015) (139)
The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. (2001) (139)
Defective Cytochrome c-dependent Caspase Activation in Ovarian Cancer Cell Lines due to Diminished or Absent Apoptotic Protease Activating Factor-1 Activity* (2001) (139)
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition (2011) (138)
A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. (1988) (137)
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models (2019) (136)
The Somatic Genomic Landscape of Glioblastoma (2014) (135)
In silico prediction of physical protein interactions and characterization of interactome orphans (2014) (134)
Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report (2014) (134)
Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis. (2001) (134)
Pharmacodynamic Markers of Perifosine Efficacy (2007) (132)
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. (2018) (132)
Oncogenic PIK 3 CA-driven mammary tumors frequently recur via PI 3 K pathway – dependent and PI 3 K pathway – independent mechanisms (2011) (132)
Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. (2010) (131)
A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. (2017) (131)
Overcoming implementation challenges of personalized cancer therapy (2012) (130)
Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. (2000) (130)
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. (2014) (130)
Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer (2009) (129)
Expression of TTK, a novel human protein kinase, is associated with cell proliferation. (1992) (129)
ARSENIC TRIOXIDE INDUCES A BECLIN-1 INDEPENDENT AUTOPHAGIC PATHWAY VIA MODULATION OF SNON/SKIL EXPRESSION IN OVARIAN CARCINOMA CELLS (2010) (129)
Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression (2011) (128)
PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas (2017) (128)
Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. (2017) (128)
DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. (2011) (128)
Breast cancer quantitative proteome and proteogenomic landscape (2019) (127)
Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3 (2008) (127)
Perturbation Biology: Inferring Signaling Networks in Cellular Systems (2013) (127)
β-Arrestin/Ral Signaling Regulates Lysophosphatidic Acid–Mediated Migration and Invasion of Human Breast Tumor Cells (2009) (127)
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. (2019) (126)
Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. (2007) (125)
Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. (2003) (125)
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. (2009) (124)
Prevention and early detection of ovarian cancer: mission impossible? (2007) (124)
Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges (2009) (124)
Inhibition of the phosphatidylinositol‐3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma (2005) (123)
Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer (2019) (122)
Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression (2010) (122)
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation (2013) (121)
Interleukin-2 induces proliferation of T lymphocyte mutants lacking protein kinase C (1988) (121)
Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. (1999) (121)
Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. (2007) (118)
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models (2020) (118)
Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma (2014) (118)
An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. (2000) (117)
Interleukin 2-induced tyrosine phosphorylation. Interleukin 2 receptor beta is tyrosine phosphorylated. (1990) (117)
Gene Expression Signature Analysis Identifies Vorinostat as a Candidate Therapy for Gastric Cancer (2011) (116)
Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. (2005) (115)
Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2 (2010) (115)
ALK: a tyrosine kinase target for cancer therapy (2017) (113)
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. (2007) (113)
Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. (2015) (112)
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation (2019) (111)
Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. (2008) (111)
Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis (2011) (110)
Requirements for the simultaneous presence of phorbol esters and calcium ionophores in the expression of human T lymphocyte proliferation-related genes. (1987) (110)
Interaction of the Wiskott–Aldrich syndrome protein with sorting nexin 9 is required for CD28 endocytosis and cosignaling in T cells (2007) (109)
Rab GTPases implicated in inherited and acquired disorders. (2011) (108)
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies (2016) (108)
Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. (1992) (108)
Building a personalized medicine infrastructure at a major cancer center. (2013) (107)
The cyclosporins inhibit lymphocyte activation at more than one site. (1987) (106)
Activation and interaction with protein kinase C of a cytoplasmic tyrosine kinase, Itk/Tsk/Emt, on Fc epsilon RI cross-linking on mast cells. (1995) (106)
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set (2016) (105)
cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes (2012) (105)
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. (2011) (104)
Bayesian Inference of Signaling Network Topology in a Cancer Cell Line (2012) (103)
Immuno-genomic landscape of osteosarcoma (2020) (103)
Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy (2019) (103)
Identification of a Phosphothionate Analogue of Lysophosphatidic Acid (LPA) as a Selective Agonist of the LPA3 Receptor* (2003) (103)
Erratum : The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (Cell Reports (2018) 23(1) (313–326.e5) (S2211124718304364) (10.1016/j.celrep.2018.03.075)) (2018) (103)
Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies (2015) (103)
Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma (2005) (103)
Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer (2009) (103)
Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. (2006) (102)
CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features (2013) (102)
Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer (2014) (102)
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. (2002) (102)
ATX-LPA receptor axis in inflammation and cancer (2009) (101)
The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells (2005) (101)
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. (2014) (101)
Sex-associated molecular differences for cancer immunotherapy (2020) (101)
Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2 (2002) (101)
A plant triterpenoid, avicin D, induces autophagy by activation of AMP-activated protein kinase (2007) (101)
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. (2015) (101)
The EMT/ITK/TSK (EMT) tyrosine kinase is activated during TCR signaling: LCK is required for optimal activation of EMT. (1996) (101)
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome (2005) (101)
Assessing BRCA carrier probabilities in extended families. (2006) (100)
Multiplatform-based Molecular Subtypes of Non-Small Cell Lung Cancer (2016) (100)
A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. (2017) (100)
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer (2011) (99)
High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays (2009) (99)
The SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory receptor CD28. (1997) (98)
ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers (2003) (98)
Clinical actionability enhanced through deep targeted sequencing of solid tumors. (2015) (96)
Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer (2013) (96)
Impairment of T cell activation in burn patients: a possible mechanism of thermal injury-induced immunosuppression. (1986) (96)
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. (2003) (95)
Yes‐associated protein 1 and transcriptional coactivator with PDZ‐binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma (2016) (95)
A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance (2011) (95)
Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance (2015) (94)
EGR1 and the ERK‐ERF axis drive mammary cell migration in response to EGF (2012) (94)
Lysophosphatidic acid production and action: Validated targets in cancer? (2004) (93)
Evidence for defective transmembrane signaling in B cells from patients with Wiskott-Aldrich syndrome. (1992) (93)
Interleukin 2-induced lymphocyte proliferation is independent of increases in cytosolic-free calcium concentrations. (1985) (93)
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma (2006) (93)
Comprehensive Characterization of Alternative Polyadenylation in Human Cancer. (2018) (92)
Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer (2005) (92)
Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma (2006) (92)
Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression (2011) (92)
Effect of lysophospholipids on signaling in the human Jurkat T cell line (1995) (92)
RNA editing derived epitopes function as cancer antigens to elicit immune responses (2018) (92)
Downregulation of SMG-1 in HPV-Positive Head and Neck Squamous Cell Carcinoma Due to Promoter Hypermethylation Correlates with Improved Survival (2012) (92)
Comprehensive characterization of circular RNAs in ~ 1000 human cancer cell lines (2019) (92)
Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. (2007) (91)
Interleukin 2 induces a rapid increase in intracellular pH through activation of a Na+/H+ antiport. Cytoplasmic alkalinization is not required for lymphocyte proliferation. (1985) (91)
Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set (2010) (90)
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer (2014) (90)
Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor (2009) (90)
Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer (2007) (89)
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer (2008) (89)
The Emerging Role of the RAB25 Small GTPase in Cancer (2009) (89)
Molecular characterization of hNRP, a cDNA encoding a human nucleosome-assembly-protein-I-related gene product involved in the induction of cell proliferation. (1994) (89)
Characterization of the role for calcium influx in mitogen‐induced triggering of human T cells. Identification of calcium‐dependent and calcium‐independent signals (1986) (89)
Erratum: Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (Cell Reports (2017) 18(11) (2780–2794) (S2211124717302140) (10.1016/j.celrep.2017.02.033)) (2017) (88)
Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks (2015) (88)
A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners (2006) (88)
Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. (2015) (88)
Vanadate stimulates oxygen consumption and tyrosine phosphorylation in electropermeabilized human neutrophils. (1990) (88)
EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. (2018) (87)
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. (2002) (87)
Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy (2020) (87)
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics (2016) (87)
Expression of p16 induces transcriptional downregulation of the RB gene (1998) (86)
Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling* (2004) (86)
An expanded universe of cancer targets (2021) (86)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. (2018) (86)
Interleukin 2 does not induce phosphatidylinositol hydrolysis in activated T cells. (1986) (85)
PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis (2020) (85)
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome (2017) (85)
Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: Accurate detection of CA19‐9 levels in pancreatic cancer (2008) (84)
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer (2015) (82)
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. (2012) (82)
Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). (1999) (82)
Transforming growth factor‐beta inhibits proliferation of human ovarian cancer cells obtained from ascites (1994) (82)
Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. (2016) (81)
Transcriptional Activation of the Proglucagon Gene by Lithium and β-Catenin in Intestinal Endocrine L Cells* (2003) (81)
Targeting PI3K-AKT pathway for cancer therapy. (2003) (81)
Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells (2008) (81)
Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. (2000) (81)
Lysophosphatidylcholine Stimulates Activator Protein 1 and the c-Jun N-terminal Kinase Activity* (1997) (79)
Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene α in Ovarian Cancer (2006) (79)
Identification, cloning, and characterization of a novel human T-cell-specific tyrosine kinase located at the hematopoietin complex on chromosome 5q. (1993) (79)
Functional variomics and network perturbation: connecting genotype to phenotype in cancer (2017) (79)
A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma (2014) (78)
Mitogens trigger a calcium-independent signal for proliferation in phorbol-ester-treated lymphocytes (1985) (78)
Functional LCK Is Required for Optimal CD28-mediated Activation of the TEC Family Tyrosine Kinase EMT/ITK (*) (1996) (77)
Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57Kip2 (2012) (77)
Src promotes estrogen-dependent estrogen receptor α proteolysis in human breast cancer (2007) (76)
Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. (2010) (76)
Tat‐activating regulatory DNA‐binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520 (2013) (76)
Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers (2018) (76)
Effects of costimulator on immune responses in vitro. (1978) (75)
Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. (1996) (75)
PTK6 Regulates IGF-1-Induced Anchorage-Independent Survival (2010) (75)
Network Analysis of the Focal Adhesion to Invadopodia Transition Identifies a PI3K-PKCα Invasive Signaling Axis (2012) (75)
Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma (2012) (75)
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†. (2014) (74)
High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients (2012) (74)
Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. (2014) (74)
In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. (2001) (74)
Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. (1991) (73)
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. (2012) (73)
Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. (2017) (73)
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System (2016) (73)
Mask Is Required for the Activity of the Hippo Pathway Effector Yki/YAP (2013) (72)
Overexpression of kallikrein 10 in epithelial ovarian carcinomas. (2003) (72)
Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents (2012) (72)
Guanine nucleotides induce tyrosine phosphorylation and activation of the respiratory burst in neutrophils. (1989) (72)
Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress (2012) (72)
Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. (2014) (72)
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. (2016) (72)
Personalizing therapy for ovarian cancer: BRCAness and beyond. (2010) (72)
Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. (2016) (72)
Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy (2015) (71)
Uptake of extracellular Ca2+ and not recruitment from internal stores is essential for T lymphocyte proliferation (1988) (70)
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling (2011) (70)
Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. (2001) (70)
Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression. (1990) (69)
CD28 delivers costimulatory signals independently of its association with phosphatidylinositol 3-kinase. (1995) (69)
Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression (2007) (69)
Combined Src and Aromatase Inhibition Impairs Human Breast Cancer Growth In vivo and Bypass Pathways Are Activated in AZD0530-Resistant Tumors (2009) (69)
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation (2014) (68)
Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. (2014) (68)
Serial dilution curve: a new method for analysis of reverse phase protein array data (2009) (68)
Characterization of the requirements for human T cell mitogenesis by using suboptimal concentrations of phytohemagglutinin. (1985) (68)
Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. (2012) (67)
Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells (2001) (67)
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. (2014) (67)
Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. (1998) (67)
Telomere 3′ overhang‐specific DNA oligonucleotides induce autophagy in malignant glioma cells (2007) (67)
Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer (2018) (66)
Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. (2007) (66)
Tyrosine phosphorylation is an obligatory event in IL-2 secretion. (1990) (66)
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase (2014) (66)
Structure-activity relationships of fluorinated lysophosphatidic acid analogues. (2005) (66)
Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer (2012) (66)
Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma (2009) (66)
An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays (2012) (66)
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer (2012) (65)
Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling (2013) (65)
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity (2002) (65)
Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer (2010) (65)
Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma (2018) (65)
Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis (2014) (65)
Predicting time to ovarian carcinoma recurrence using protein markers. (2013) (64)
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT, and MEK/ERK signaling in breast cancer (2014) (64)
Rab25 in cancer: a brief update. (2012) (64)
RET fusion as a novel driver of medullary thyroid carcinoma. (2015) (63)
Functional platelet-activating factor receptors are expressed by monocytes and granulocytes but not by resting or activated T and B lymphocytes from normal individuals or patients with asthma. (1994) (63)
Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins (2013) (63)
Growth Signal Transduction by the Human Interleukin-2 Receptor Requires Cytoplasmic Tyrosines of the β Chain and Non-tyrosine Residues of the γc Chain (*) (1995) (62)
Activation of phospholipase C in human B cells is dependent on tyrosine phosphorylation. (1991) (62)
Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape (2017) (62)
The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. (1999) (62)
Benzyl and Naphthalene Methylphosphonic Acid Inhibitors of Autotaxin with Anti‐invasive and Anti‐metastatic Activity (2011) (62)
Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. (2009) (61)
Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis1 (2003) (61)
Role of membrane potential in the response of human T lymphocytes to phytohemagglutinin. (1987) (61)
Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. (2016) (61)
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes (2012) (61)
Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. (2006) (60)
AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. (2008) (60)
The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. (2006) (60)
Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy (2010) (60)
hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness (2014) (60)
ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. (2005) (60)
BRD4 facilitates replication stress-induced DNA damage response (2018) (60)
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. (2017) (59)
TransVar: a multilevel variant annotator for precision genomics (2015) (59)
Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR (2011) (59)
AKT‐dependent phosphorylation of Niban regulates nucleophosmin‐ and MDM2‐mediated p53 stability and cell apoptosis (2012) (59)
Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women (2013) (58)
Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death (2011) (58)
Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer (2014) (58)
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. (2015) (58)
Functional annotation of rare gene aberration drivers of pancreatic cancer (2016) (58)
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. (2019) (57)
Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. (2000) (57)
Cell cycle progression out of G1 sensitizes primary-cultured nontransformed T cells to TCR-mediated apoptosis. (1996) (57)
PI3K pathway-directed therapeutic strategies in cancer. (2010) (57)
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes (2016) (56)
Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. (2008) (56)
Site-specific activation of AKT protects cells from death induced by glucose deprivation (2014) (56)
COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms (2019) (56)
A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy (2008) (56)
Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. (1999) (56)
Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence (2010) (55)
Integrative epidemiology: from risk assessment to outcome prediction. (2005) (54)
The role of macrophages in thymocyte mitogenesis. (1976) (54)
Regulation of the PI3K pathway through a p85α monomer–homodimer equilibrium (2015) (54)
Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (Interleukin 2): in vivo activity. (1980) (54)
Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo (2012) (54)
MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition (2012) (54)
Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. (2014) (54)
Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. (2014) (53)
Of Spiders and Crabs: The Emergence of Lysophospholipids and Their Metabolic Pathways as Targets for Therapy in Cancer (2006) (53)
Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. (2008) (53)
Evidence That Phosphatidylinositol 3-Kinase- and Mitogen-activated Protein Kinase Kinase-4/c-Jun NH2-terminal Kinase-dependent Pathways Cooperate to Maintain Lung Cancer Cell Survival* (2003) (53)
Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes (2018) (53)
CD28-mediated signaling in vivo prevents activation-induced apoptosis in the thymus and alters peripheral lymphocyte homeostasis. (1995) (53)
Selective Genomic Copy Number Imbalances and Probability of Recurrence in Early-Stage Breast Cancer (2011) (52)
Differential Roles of Phosphoinositide-Dependent Protein Kinase-1 and Akt1 Expression and Phosphorylation in Breast Cancer Cell Resistance to Paclitaxel, Doxorubicin, and Gemcitabine (2006) (52)
A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. (2014) (52)
Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. (2014) (52)
Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. (2007) (52)
A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells. (2000) (51)
The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. (2015) (51)
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells (2018) (51)
Generation of cytotoxic lymphocytes to syngeneic tumor by using co-stimulator (Interleukin 2). (1980) (51)
Role of RPL39 in Metaplastic Breast Cancer (2017) (51)
Assay of Rab25 function in ovarian and breast cancers. (2005) (50)
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer (2015) (50)
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors (2014) (50)
Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling (2011) (50)
Death-associated protein kinase 1 promotes growth of p53-mutant cancers. (2015) (50)
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients (2014) (50)
Phosphatidylinositol 3-kinase is required for CD28 but not CD3 regulation of the TEC family tyrosine kinase EMT/ITK/TSK: functional and physical interaction of EMT with phosphatidylinositol 3-kinase. (1998) (50)
Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer (2010) (49)
Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477)) (2014) (49)
LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer (2013) (49)
ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. (2016) (49)
miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. (2019) (49)
Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. (2016) (49)
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. (2003) (49)
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. (2010) (49)
Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity. (2003) (49)
Androgen Regulation of 5α-Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer Prevention (2011) (49)
The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment (2016) (49)
Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. (2020) (49)
Somatic Mutations of PIK3R1 Promote Gliomagenesis (2012) (48)
Proteomic Characterization of Head and Neck Cancer Patient–Derived Xenografts (2015) (48)
Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. (2017) (48)
SH2-dependent association of phosphatidylinositol 3'-kinase 85-kDa regulatory subunit with the interleukin-2 receptor beta chain. (1994) (48)
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. (2019) (47)
Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C α activity (2001) (47)
PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. (2009) (47)
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. (2015) (47)
Rab 25 Associates with a 5 b 1 Integrin to Promote Invasive Migration in 3 D Microenvironments (47)
Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo (2018) (47)
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity (2017) (47)
Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis (2009) (46)
Precision Oncology Decision Support: Current Approaches and Strategies for the Future (2018) (46)
Glycogen Synthase Kinase 3β Is a Negative Regulator of Growth Factor-induced Activation of the c-Jun N-terminal Kinase* (2004) (46)
PTEN loss is a context‐dependent outcome determinant in obese and non‐obese endometrioid endometrial cancer patients (2015) (46)
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm (2017) (46)
Clinical next generation sequencing to identify actionable aberrations in a phase I program (2014) (45)
Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid (2010) (45)
Distinct histone modifications denote early stress-induced drug tolerance in cancer (2017) (45)
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes (2015) (45)
Platelet-activating factor triggers the phosphorylation and activation of MAP-2 kinase and S6 peptide kinase activity in human B cell lines. (1993) (45)
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells (2009) (45)
A tyrosine kinase physically associates with the beta-subunit of the human IL-2 receptor. (1991) (45)
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer (2020) (45)
Osmotic activation of the Na+/H+ antiport in protein kinase C-depleted lymphocytes. (1986) (45)
Specific keynote: genome copy number abnormalities in ovarian cancer. (2003) (44)
An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2 (2015) (44)
Comparison of phorbol ester/calcium ionophore and phytohemagglutinin-induced signaling in human T lymphocytes. Demonstration of interleukin 2-independent transferrin receptor gene expression. (1988) (44)
A sequence-based survey of the complex structural organization of tumor genomes (2008) (44)
Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells. (2001) (44)
Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. (2017) (44)
Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. (2009) (44)
Frequency of mesenchymal‐epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide‐3‐kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer (2013) (43)
BSTA Promotes mTORC2-Mediated Phosphorylation of Akt1 to Suppress Expression of FoxC2 and Stimulate Adipocyte Differentiation (2013) (43)
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1–IRF1–TRIM28 Signaling Axis, Exerting Antitumor Efficacy (2020) (43)
Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer (2013) (43)
Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. (2014) (43)
Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer (2014) (43)
AMPK‐mediated phosphorylation of murine p27 at T197 promotes binding of 14‐3‐3 proteins and increases p27 stability (2010) (43)
Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer (2014) (43)
cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer (2014) (42)
Exploratory Analysis of the Copy Number Alterations in Glioblastoma Multiforme (2008) (42)
Development of a robust classifier for quality control of reverse-phase protein arrays (2015) (42)
EVI1 splice variants modulate functional responses in ovarian cancer cells (2013) (42)
Abortive Autophagy Induces Endoplasmic Reticulum Stress and Cell Death in Cancer Cells (2012) (42)
Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. (2016) (42)
Genomic amplicons target vesicle recycling in breast cancer. (2009) (42)
Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis (2020) (42)
Development and Validation of a Prognostic Gene-Expression Signature for Lung Adenocarcinoma (2012) (42)
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer (2019) (42)
Increase of serum interleukin 2 receptor level in thermally injured patients. (1989) (42)
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. (2018) (41)
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors (2017) (41)
Targeting KRas-dependent tumor growth, circulating tumor cells and metastasis in vivo by clinically significant miR-193a-3p (2016) (41)
A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. (2005) (41)
Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. (2017) (41)
Sex differences in oncogenic mutational processes (2019) (41)
Impaired expression of interleukin-2 receptor (IL2R) in the immunosuppressed burned patient: reversal by exogenous IL2. (1987) (41)
CD28-mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3-kinase, and protein kinase C. (1996) (40)
The degree of intratumor mutational heterogeneity varies by primary tumor sub-site (2016) (40)
pp60c-src expression is induced by activation of normal human T lymphocytes. (1995) (40)
Immune deficiency following thermal trauma is associated with apoptotic cell death (1995) (40)
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response (2017) (40)
Lysophosphatidic acid (LPA)‐induced vasodilator‐stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC‐3 prostate cancer cells (2008) (40)
Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck. (2007) (40)
An Inherent Role of Integrin-Linked Kinase-Estrogen Receptor α Interaction in Cell Migration (2006) (39)
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies (2018) (39)
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer (2020) (39)
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer (2017) (39)
Physical Association of PDK1 with AKT1 Is Sufficient for Pathway Activation Independent of Membrane Localization and Phosphatidylinositol 3 Kinase (2010) (39)
An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation (2014) (39)
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance (2016) (39)
Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling (2017) (38)
Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression (2016) (38)
Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC). (2014) (38)
Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure (2015) (38)
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors (2018) (38)
Interleukin 2 activates a receptor-associated protein kinase. (1987) (38)
Elafin drives poor outcome in high grade serous ovarian cancers and basal-like breast tumors (2013) (38)
YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway. (2017) (38)
Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer (2012) (38)
TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data* (2019) (37)
Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response (2020) (37)
Immunosuppression follows systemic T lymphocyte activation in the burn patient (1991) (37)
Stem cell-ness: a "magic marker" for cancer. (2005) (37)
LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients (2012) (37)
Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. (2000) (37)
Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation. (2014) (37)
Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. (2012) (36)
Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules (2014) (36)
Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin (2018) (36)
Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. (2016) (36)
Stapled peptide inhibitors of RAB25 target context-specific phenotypes in cancer (2017) (36)
Comprehensive assessment of computational algorithms in predicting cancer driver mutations (2020) (36)
Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations (2013) (36)
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. (2020) (36)
A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. (2019) (35)
MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis (2019) (35)
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. (2021) (35)
Bias from removing read duplication in ultra-deep sequencing experiments (2014) (35)
High multiplex, digital spatial profiling of proteins and RNA in fixed tissue using genomic detection methods (2019) (34)
Activation of the Na+/H+ antiport is not required for lectin-induced proliferation of human T lymphocytes. (1986) (34)
Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer (2015) (34)
Transmembrane signaling by the interleukin-2 receptor: progress and conundrums. (1993) (34)
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women (2015) (34)
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. (2013) (34)
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer (2022) (34)
EGFR mediates LPA‐induced proteolytic enzyme expression and ovarian cancer invasion: Inhibition by resveratrol (2013) (34)
Cyclosporin A inhibits initiation but not progression of human T cell proliferation triggered by phorbol esters and calcium ionophores. (1988) (34)
Point mutations of protein kinases and individualised cancer therapy (2006) (34)
Protein Kinase C Quality Control by Phosphatase PHLPP1 Unveils Loss-of-Function Mechanism in Cancer. (2019) (33)
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer (2015) (33)
Systematic analysis of genotype‐specific drug responses in cancer (2012) (33)
RCP induces Slug expression and cancer cell invasion by stabilizing β1 integrin (2017) (33)
Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT (2016) (33)
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 (2016) (33)
YB‐1 Transforms Human Mammary Epithelial Cells Through Chromatin Remodeling Leading to the Development of Basal‐Like Breast Cancer (2014) (33)
Lysophosphatidic Acid Signaling Protects Pulmonary Vasculature From Hypoxia-Induced Remodeling (2012) (32)
Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. (2009) (32)
Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. (2007) (32)
Functional consequence of the MET-T1010I polymorphism in breast cancer (2014) (32)
Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK. (1998) (32)
Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. (2001) (32)
Neither the LCK nor the FYN kinases are obligatory for IL-2-mediated signal transduction in HTLV-I-infected human T cells. (1992) (32)
Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers (2019) (32)
"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. (2017) (32)
Dissociation of cytokine signals for proliferation and apoptosis. (1997) (32)
Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). (2011) (31)
Implementing a comprehensive translational oncology platform: from molecular testing to actionability (2018) (31)
Bioinformatics and systems biology (2012) (31)
Lysophosphatidic acid and ovarian cancer: a paradigm for tumorogenesis and patient management. (2001) (31)
Retrospective Review of MET Gene Mutations (2015) (31)
Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. (1999) (31)
Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect. (2015) (31)
Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy. (2017) (31)
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer (2018) (31)
Expression of endogenous granzyme B in a subset of human primary breast carcinomas (2003) (31)
Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. (2015) (31)
Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype. (2018) (30)
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. (2015) (30)
Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming (2018) (30)
Exposing the cancer genome atlas as a SPARQL endpoint (2010) (30)
Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. (2010) (30)
IL-2-induced expression of TTK, a serine, threonine, tyrosine kinase, correlates with cell cycle progression. (1994) (30)
New era of integrated cancer biomarker discovery using reverse-phase protein arrays. (2016) (30)
p202 prevents apoptosis in murine AKR-2B fibroblasts. (1998) (30)
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. (2016) (30)
Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: A role in ovarian pathogenesis (2008) (30)
Autophosphorylation of Akt at Threonine 72 and Serine 246 (2006) (30)
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. (2014) (30)
Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness (2019) (30)
AKT isoform-specific expression and activation across cancer lineages (2018) (30)
Differential signaling by an anti-p185(HER2) antibody and heregulin. (2000) (30)
EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. (2021) (30)
Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression. (2016) (29)
Loss-of-function screens of druggable targetome against cancer stem–like cells (2016) (29)
Frequent Mutation of the PI 3 K Pathway in Head and Neck Cancer Defi nes Predictive Biomarkers (2013) (29)
General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. (2003) (29)
Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers. (2006) (29)
Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. (2012) (29)
Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer. (2017) (29)
Induction of competence and progression signals in human T lymphocytes by phorbol esters and calcium ionophores (1988) (29)
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. (2015) (29)
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference (2019) (29)
A curated census of autophagy-modulating proteins and small molecules (2014) (29)
Survival of Cancer Stem-Like Cells Under Metabolic Stress via CaMK2α-mediated Upregulation of Sarco/Endoplasmic Reticulum Calcium ATPase Expression (2017) (29)
Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. (2010) (29)
The Src-homology domain 2-bearing protein tyrosine phosphatase-1 inhibits antigen receptor-induced apoptosis of activated peripheral T cells. (1999) (28)
CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. (1997) (28)
Expression of ras oncogene leads to down‐regulation of protein kinase C (1990) (28)
Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. (2020) (28)
Cardiac glycosides display selective efficacy for STK11 mutant lung cancer (2016) (28)
Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer (2019) (28)
Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer (2016) (28)
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response (2021) (28)
High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype (2016) (27)
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial (2014) (27)
Soluble interleukin 2-receptor alpha secretion is related to altered interleukin 2 production in thermally injured patients. (1991) (27)
A Time‐Series DDP for Functional Proteomics Profiles (2012) (27)
RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC (2020) (27)
HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. (2016) (27)
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer (2014) (26)
BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. (2020) (26)
Methylation and Messenger RNA Expression of p15INK4b but Not p16INK4a Are Independent Risk Factors for Ovarian Cancer (2005) (26)
Therapeutic potential of phosphoinositide 3-kinase inhibitors (2004) (26)
Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice. (1998) (26)
HIV infection in vitro enhances the activity of src-family protein tyrosine kinases. (1996) (26)
Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors (2011) (26)
Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer (2011) (26)
Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma (2017) (25)
Molecular therapeutics: promise and challenges. (2004) (25)
Tyrosine phosphorylation is an essential event in the stimulation of B lymphocytes by Staphylococcus aureus Cowan I. (1991) (25)
Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. (2017) (25)
MERIT: Systematic Analysis and Characterization of Mutational Effect on RNA Interactome Topology (2019) (25)
ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. (2011) (25)
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma (2018) (25)
Clinical Use of Precision Oncology Decision Support. (2017) (25)
ERa-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer (2011) (25)
Phosphorothioate Analogues of Alkyl Lysophosphatidic Acid as LPA3 Receptor‐Selective Agonists (2006) (25)
Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C‐Raf and B‐Raf isoforms by FGFR and MC1R (2008) (25)
Phase II, 2‐stage, 2‐arm, PIK3CA mutation stratified trial of MK‐2206 in recurrent endometrial cancer (2019) (24)
Neomorphic mutations create therapeutic challenges in cancer (2017) (24)
Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development* (2016) (24)
Homozygous deletion of glycogen synthase kinase 3β bypasses senescence allowing Ras transformation of primary murine fibroblasts (2008) (24)
Spatial Normalization of Reverse Phase Protein Array Data (2014) (24)
Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. (2010) (24)
Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types (2016) (24)
Large-scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines (2020) (24)
Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery (2018) (23)
Transmembrane signalling by interleukin 2. (1991) (23)
In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer (2018) (23)
Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling. (2006) (23)
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion (2016) (23)
Bead transfection: rapid and efficient gene transfer into marrow stromal and other adherent mammalian cells. (1993) (23)
An emerging toolkit for targeted cancer therapies. (2012) (23)
The regulatory role of interleukin 2-responsive T lymphocytes on human marrow granulopoiesis. (1987) (23)
Lymphocyte function in human bone marrow. I. Characterization of two T cell populations regulating immunoglobulin secretion. (1985) (23)
Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening (2017) (23)
Systems approach to rational combination therapy: PARP inhibitors. (2020) (23)
Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. (2010) (23)
Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). (2013) (22)
Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort (2015) (22)
Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway (2016) (22)
ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. (2017) (22)
Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival (2017) (22)
OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets (2014) (22)
A Comprehensive Comparison of Normalization Methods for Loading Control and Variance Stabilization of Reverse-Phase Protein Array Data (2014) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
MITI minimum information guidelines for highly multiplexed tissue images (2021) (22)
The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3. (2010) (21)
The diacylglycerol analogue, 1,2-sn-dioctanoylglycerol, induces an increase in cytosolic free Ca2+ and cytosolic acidification of T lymphocytes through a protein kinase C-independent process. (1989) (21)
Precision oncology: neither a silver bullet nor a dream. (2017) (21)
Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions (2007) (21)
Erratum: Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer (2016) (21)
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. (2019) (21)
Oxygen sensor boosts growth factor signaling (2009) (21)
Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer (2015) (21)
Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer (2011) (21)
Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium (2010) (21)
p202 self‐associates through a sequence conserved among the members of the 200‐family proteins (1998) (21)
Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. (1994) (21)
Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. (2002) (21)
Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis (2020) (21)
Data integration gets 'Sloppy' (2006) (21)
A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway (2015) (21)
Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. (2021) (21)
The tyrosine kinase activity of the C‐erbB‐2 gene product (p185) is required for growth inhibition by anti‐p185 antibodies but not for the cytotoxicity of an anti‐p185‐ricin‐a chain immunotoxin (1994) (21)
Interactions between tumor cells and microenvironment in breast cancer: A new opportunity for targeted therapy (2012) (21)
Small Molecule ErbB Inhibitors Decrease Proliferative Signaling and Promote Apoptosis in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (2013) (20)
Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. (1998) (20)
Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma (2020) (20)
A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation (2016) (20)
Specific keynote: molecular therapeutics in ovarian cancer. (2003) (20)
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer (2015) (20)
MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling (2020) (20)
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment (2010) (20)
Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. (2008) (20)
Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women (2015) (20)
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment (2022) (19)
Clinical outcomes based on multigene profiling in metastatic breast cancer patients (2016) (19)
Physiologic activation of protein kinase C limits IL-2 secretion. (1989) (19)
Interleukin-2 secretion and transmembrane signalling in burned patients. (1988) (19)
An inherent role of integrin-linked kinase-estrogen receptor alpha interaction in cell migration. (2006) (19)
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival (2014) (19)
Soluble interleukin‐2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer (1995) (19)
Molecular heterogeneity at the network level: high-dimensional testing, clustering and a TCGA case study (2017) (19)
GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity (2019) (19)
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer (2013) (19)
Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. (1996) (19)
Homologous Recombination De fi ciency ( HRD ) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer (2016) (19)
Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells. (1985) (19)
Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer. (2018) (19)
Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma (2021) (18)
Expression of human tyrosine kinase-negative epidermal growth factor receptor amplifies signaling through endogenous murine epidermal growth factor receptor. (1993) (18)
Differences in Gene and Protein Expression and the Effects of Race/Ethnicity on Breast Cancer Subtypes (2013) (18)
Involvement of the SHP-1 tyrosine phosphatase in regulating B lymphocyte antigen receptor signaling, proliferation and transformation. (1999) (18)
Erratum: The SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory receptor CD28 (Journal of Immunology (1997) 159 (3220-3227)) (1999) (18)
Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. (2010) (18)
Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors (2019) (18)
A Systems Approach to Analysis of Molecular Complexity in Breast Cancer (2009) (18)
Quantitative proteomic analysis in breast cancer. (2011) (18)
The rise of genomic profiling in ovarian cancer (2016) (18)
Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo (2017) (18)
Proteomic classification of breast cancer. (2012) (18)
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer (2017) (18)
Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies* (2018) (18)
TYROSINE PHOSPHORYLATION OF P 85 RELIEVES ITS INHIBITORY ACTIVITY ON PHOSPHATIDYLINOSITOL 3-KINASE (2001) (18)
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. (2019) (17)
Transient commensal clonal interactions can drive tumor metastasis (2020) (17)
Modulators of lysophosphatidic acid signalling (2003) (17)
Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors (2020) (17)
p85β regulates autophagic degradation of AXL to activate oncogenic signaling (2020) (17)
PKC iota promotes ovarian tumor progression through deregulation of cyclin E (2015) (17)
Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. (2014) (17)
Network inference using steady-state data and Goldbeter-Koshland kinetics (2012) (17)
Genomic components of carcinogenesis. (1993) (17)
Fibroblast–tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways (2020) (17)
In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response (2021) (17)
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options (2019) (16)
PI 3 K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer (2011) (16)
Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. (2004) (16)
Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. (2008) (16)
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts (2020) (16)
Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors (2021) (16)
Proteomic patterns in serum and identification of ovarian cancer (2002) (16)
Binding of interleukin 2 to its 75-kDa intermediate affinity receptor is sufficient to activate Na+/H+ exchange. (1987) (16)
Cancer driver mutation prediction through Bayesian integration of multi-omic data (2018) (15)
Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling (2020) (15)
Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro (2018) (15)
Advancing Drug Development in Gynecologic Malignancies (2019) (15)
Effect of GTP gamma S on insulin binding and tyrosine phosphorylation in liver membranes and L6 muscle cells. (1990) (15)
Antigen-induced Ca2+ signaling and desensitization in B cells. (1990) (15)
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models (2021) (15)
Erratum: Predicting time to ovarian carcinoma recurrence using protein markers (Journal of Clinical Investigation (2013) 123:9 (3740-3750) DOI: 10.1172/JCI68509) (2013) (15)
Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer. (2020) (15)
Bayesian models based on test statistics for multiple hypothesis testing problems (2008) (15)
Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes (2013) (15)
IL‐2 regulation of soluble IL‐2 receptor levels following thermal injury (1992) (15)
Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors (2003) (15)
Agents That Stabilize Mutated von Hippel–Lindau (VHL) Protein (2012) (14)
391PPhase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer (2017) (14)
Detection algorithm for the validation of human cell lines (2012) (14)
The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression (2019) (14)
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma (2018) (14)
Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. (2003) (14)
Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression (2020) (14)
Translational research--traffic on the bridge. (2001) (14)
Prognostic relevance of acquired uniparental disomy in serous ovarian cancer (2015) (14)
Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation. (2018) (14)
Ras-superfamily GTP-ases in ovarian cancer. (2009) (14)
Chronic myeloid leukemia arising in a progenitor common to T cells and myeloid cells. (1990) (14)
Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity (2018) (14)
Activation of the Na+/H+ antiport is not required for epidermal growth factor-dependent gene expression, growth inhibition or proliferation in human breast cancer cells. (1989) (13)
Growth signal transduction by the human interleukin-2 receptor requires cytoplasmic tyrosines of the beta chain and non-tyrosine residues of the gamma c chain. (1995) (13)
Prospective Clinical Sequencing of Adult Glioma (2019) (13)
Personalized Integrated Network Modeling of the Cancer Proteome Atlas (2018) (13)
Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p. (2018) (13)
Alkoxymethylenephosphonate Analogues of (Lyso)phosphatidic Acid Stimulate Signaling Networks Coupled to the LPA2 Receptor (2007) (13)
RPPAML/RIMS: A metadata format and an information management system for reverse phase protein arrays (2008) (13)
Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases (2019) (13)
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer (2021) (13)
Profiling of immune features to predict immunotherapy efficacy (2021) (13)
Mitogenic response of human thymocytes: identification of functional Ca2+-dependent and independent signals. (1986) (13)
AKT Pathway Genes Define 5 Prognostic Subgroups in Glioblastoma (2014) (13)
A deep learning model observer for use in alterative forced choice virtual clinical trials (2018) (13)
Ovarian Epithelial Cancer Cells Cleavage during Cisplatin-induced Apoptosis in Human XIAP Regulates Akt Activity and Caspase-3-dependent Updated (2001) (12)
Transforming Big Data into Cancer-Relevant Insight: An Initial, Multi-Tier Approach to Assess Reproducibility and Relevance (2016) (12)
Ovarian Cancer: Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer (2006) (12)
Robust Selection Algorithm (RSA) for Multi-Omic Biomarker Discovery; Integration with Functional Network Analysis to Identify miRNA Regulated Pathways in Multiple Cancers (2015) (12)
T-lymphocyte proliferation: tyrosine kinases in interleukin 2 signal transduction. (1992) (12)
Somatic BRCA status in ovarian tumors. (2016) (12)
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory (2017) (12)
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics (2021) (12)
Halothane-dependent release of intracellular Ca2+ in blood cells in malignant hyperthermia. (1990) (12)
Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy (2012) (12)
Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. (2021) (12)
Mechanical Stress Signaling in Pancreatic Cancer Cells Triggers p38 MAPK- and JNK-Dependent Cytoskeleton Remodeling and Promotes Cell Migration via Rac1/cdc42/Myosin II (2021) (12)
Response of human B cells to different anti‐immunoglobulin isotypes: Absence of a correlation between early activation events and cell proliferation (1987) (12)
Quantitative analysis of the proliferative activity induced in murine thymocytes by concanavalin A. (1976) (12)
Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. (2019) (11)
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors (2022) (11)
Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D (2014) (11)
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors (2021) (11)
Physician interpretation of genomic test results and treatment selection (2018) (11)
The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer (2016) (11)
An octapeptide analogue of HIV gp120 modulates protein tyrosine kinase activity in activated peripheral blood T lymphocytes (1995) (11)
Antigen-induced Fc receptor-dependent and -independent B cell desensitization. An elevation in [Ca2+]i is not sufficient and protein kinase C activation is not required for these pathways of surface IgM-mediated desensitization. (1991) (11)
Abstract 4262: A pan-cancer proteomic analysis of The Cancer Genome Atlas (TCGA) project (2014) (11)
Genome-Wide Analysis of Head and Neck Squamous Cell Carcinomas Reveals HPV, TP53, Smoking and Alcohol-Related Allele-Based Acquired Uniparental Disomy Genomic Alterations1 (2019) (11)
Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1 (2017) (11)
Interrelationship between signals transduced by phytohemagglutinin and interleukin 1 (1990) (11)
Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function (2016) (11)
Contrasting Requirements for IL-2 Production, IL-2 Receptor Expression, and Lymphocyte Proliferation: The Role of Calcium-Dependent and Calcium-Independent Signals (1987) (11)
Mechanisms underlying chemoprevention of ovarian cancer. (2002) (11)
Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1 (2020) (10)
Molecular approaches to management of epithelial ovarian cancer. (2000) (10)
Role of aberrant sialylation of chronic myeloid leukemia granulocytes on binding and signal transduction by chemotactic peptides and colony stimulating factors. (1993) (10)
Drosophila in cancer research: to boldly go where no one has gone before (2011) (10)
Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions inKRASmutant cancers (2020) (10)
IL-2 secretion is pertussis toxin sensitive in a T lymphocyte hybridoma. (1989) (10)
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. (2019) (10)
The v-raf oncogene enhances tumorigenicity and suppresses differentiation in vivo in a rat hepatocyte cell line. (1993) (10)
Large-Scale Drug Screens Support Precision Medicine. (2015) (10)
Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients (2017) (10)
In Vitro and in Vivo Antitumor Effect of the Anti-CD 26 Monoclonal Antibody 1 F 7 on Human CD 30 1 Anaplastic Large Cell T-Cell Lymphoma Karpas 2991 (2001) (10)
Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis (2018) (9)
Predicting Cancer Cell Line Dependencies From the Protein Expression Data of Reverse-Phase Protein Arrays (2020) (9)
An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer (2020) (9)
A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs (2022) (9)
TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data. (2019) (9)
Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients. (2008) (9)
Functional lipidomics: Lysophosphatidic acid as a target for molecular diagnosis and therapy of ovarian cancer (2005) (9)
Spatially interacting phosphorylation sites and mutations in cancer (2021) (9)
Hormonal Modulation of ESR1 Mutant Metastasis (2020) (9)
Targeted therapy of AML new concepts. (2004) (9)
Modeling Heterogeneity of Triple‐Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance (2020) (9)
The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer (2019) (9)
In Vivo and in Vitro Ovarian Carcinoma Growth Inhibition by a Phosphatidylinositol 3-Kinase Inhibitor ( LY 294002 ) 1 (2000) (9)
Unraveling the regulatory connections between two controllers of breast cancer cell fate (2014) (9)
Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors. (2014) (9)
WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway (2021) (9)
Analysis of the EDG2 Receptor Based on the Structure/Activity Relationship of LPA (2000) (9)
Role of protein kinase c in interleukin 1, anti‐T3, and mitogenic lectin‐induced interleukin 2 secretion (1989) (9)
Abstract 4342: Ultra-deep next generation sequencing (NGS) of plasma cell-free DNA (cfDNA) from patients with advanced lung cancers: results from the Actionable Genome Consortium (2016) (9)
Modulation of the Hippo pathway and organ growth by RNA processing proteins (2018) (9)
Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations (2019) (9)
A murine preclinical syngeneic transplantation model for breast cancer precision medicine (2017) (8)
Molecular determinants of post-mastectomy breast cancer recurrence (2018) (8)
Frequency of MET and PIK3CA copy number elevation and correlation with outcome in early stage breast cancer (2013) (8)
Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. (2020) (8)
Fallopian tube precursor lesions of serous ovarian carcinoma require L1CAM for dissemination and metastasis (2018) (8)
Activation of human ovarian cancer cells: role of lipid factors in ascitic fluid (1995) (8)
Cytoplasmic expression of p 21 CIP 1 / WAF 1 is correlated with IKKß overexpression in human breast cancers (8)
Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies (2021) (8)
Loss of heterozygosity (LOH) as a measure of whole-genome instability in ovarian cancer correlates with clinical outcomes. (2011) (8)
mi-IsoNet: systems-scale microRNA landscape reveals rampant isoform-mediated gain of target interaction diversity and signaling specificity (2021) (8)
Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. (2017) (8)
Inhibition of stimulus‐dependent epidermal growth factor receptor and transforming growth factor‐α mRNA accumulation by the protein kinase C inhibitor staurosporine (1989) (8)
The impact of tumor heterogeneity on patient treatment decisions. (2013) (8)
β-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer (2018) (8)
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. (2021) (8)
Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer (2013) (8)
Integrated transcriptomic–genomic tool Texomer profiles cancer tissues (2019) (8)
Correction: Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas (2015) (8)
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035) (2020) (8)
Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas (2018) (8)
Therapeutics , Targets , and Chemical Biology The RAC 1 P 29 S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF (2014) (8)
Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines (2015) (8)
Introduction: Transmembrane signaling through hematopoietin receptors: interleukin-2 and erythropoietin (1993) (7)
Molecular screening for breast cancer prevention, early detection, and treatment planning: Combining biomarkers from DNA, RNA, and protein (2006) (7)
Identification and validation of a prognostic proteomic signature for cervical cancer. (2019) (7)
Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program. (2015) (7)
Are oncogenes sufficient to cause human cancer? (2010) (7)
Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer (2000) (7)
Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines (2013) (7)
Repurposing the Pap Smear: One Step Closer to Gynecologic Cancer Screening (2013) (7)
Interleukin enhancer‐binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma (2021) (7)
Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. (2020) (7)
Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer (2021) (7)
Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics. (2021) (7)
A multi-encoder variational autoencoder controls multiple transformational features in single-cell image analysis (2022) (7)
ME-VAE: Multi-Encoder Variational AutoEncoder for Controlling Multiple Transformational Features in Single Cell Image Analysis (2021) (7)
Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer. (2014) (7)
Interleukin 2 in cell-mediated immune responses. (1980) (7)
Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer. (2015) (7)
Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer (2018) (7)
Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer (2021) (7)
Integrated Genomic Characterization of the Human Immunome in Cancer (2020) (7)
Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers. (2001) (6)
Soft Tissue Sarcoma Cells Are Highly Sensitive to AKT Blockade: A Role for p53-Independent Up-regulation of GADD45 A (2008) (6)
A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma (2022) (6)
YAP1 and TAZ Activates mTORC1 Pathway by Regulating Amino Acid Transporters in hepatocellular carcinoma (2016) (6)
Precision oncology for breast cancer through clinical trials (2021) (6)
Author Correction: Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin (2018) (6)
Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function (2021) (6)
Results of a high-throughput screen to identify compounds that modulate VHL proteostasis. (2012) (6)
Credentialing Individual Samples for Proteogenomic Analysis * (2018) (6)
Interferon and phorbol esters down‐regulate slgM expression by independent pathways (1988) (6)
Clinical outcomes based on multigene profiling in metastatic breast cancer patients. (2015) (6)
Evidence that increases in lymphocyte tyrosine phosphorylation precede cardiac allograft rejection. Effects of cyclosporine and potential use in clinical management. (1994) (6)
Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC). (2014) (5)
Adaptive response to BET inhibition induces therapeutic vulnerability to MCL1 inhibitors in breast cancer (2019) (5)
Whole exome sequencing of metaplastic breast cancer (MpBC): Effect of mutation status on survival. (2017) (5)
Cancer gene profile of metastatic breast cancer. (2012) (5)
Predicting high-risk endometrioid carcinomas using proteins (2018) (5)
Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling (2021) (5)
Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer (2021) (5)
Shrewd AKT regulation to survive (2014) (5)
Erratum: Ability to generate patient-derived breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes (PLoS ONE (2015) 10:9 (e0136851) DOI: 10.1371/journal.pone.0136851) (2016) (5)
Differential Effects of Three Small Molecules Blocking Phosphatidylinositol-3 Kinase or AKT in Hodgkin Disease Cell Lines: Induction of Apoptosis and Cell Cycle Arrest. (2004) (5)
Proteomic profiling of HPV-positive head and neck cancer to identify new candidates for targeted therapy. (2014) (5)
Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers (2015) (5)
Inhibition of the ATM / Chk 2 axis promotes cGAS / STING signaling in ARID 1 A-deficient tumors (2020) (5)
A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer. (2019) (5)
Characterization of a naturally occurring breast cancer subset enriched in EMT and stem cell characteristics (2009) (5)
Should therapy of ovarian cancer patients be individualized based on underlying genetic defects? (1999) (5)
Correlation of Snail expression and survival in patients with early-stage triple-negative breast cancer (TNBC). (2010) (5)
Interferons do not signal cells through rapid alterations in phosphatidylinositide hydrolysis, cytoplasmic free calcium, or cytoplasmic alkalinization. (1985) (5)
Lithium battery fires: implications for air medical transport. (2012) (5)
Abstract CT033: Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer (2018) (5)
Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer (2021) (5)
Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas. (2017) (5)
Mutation profling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system. (2012) (5)
Activation of Lymphocytes by Lymphokines (1990) (5)
Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma (2020) (4)
Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes (2016) (4)
Glycogen metabolism provides nutritional support to renal cancer cells under conditions of stress and may serve as a marker of response to antiangiogenic therapy with bevacizumab (2010) (4)
Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1 (2020) (4)
Cell-free DNA copy number variations as a marker for breast cancer in a large study cohort. (2013) (4)
Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations inBRCA1/2, mutations/deletions inPTENor PTEN loss, aberrations in otherBRCApathway genes, and germline mutations inBRCA1/2(not breast or ovarian cancer) (2018) (4)
Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management (2016) (4)
AKT‐dependent phosphorylation of Niban regulates nucleophosmin‐ and MDM2‐mediated p53 stability and cell apoptosis (2014) (4)
Spotlight on Clinical Response Activity of dasatinib against L 576 P KIT mutant melanoma : Molecular , cellular , and clinical correlates (2009) (4)
Methylation andMessenger RNAExpression of p 15 INK 4 b but Not p 16 INK 4 a Are Independent Risk Factors for Ovarian Cancer (2005) (4)
A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses (2022) (4)
Sustained increases in cytosolic calcium during T lymphocyte allosensitization, proliferation, and acquisition of locomotor function. (1991) (4)
Sparse Bayesian graphical models for RPPA time course data (2012) (4)
Therapeutic Clues from an Integrated Omic Assessment of East Asian Triple Negative Breast Cancers. (2019) (4)
Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas. (2022) (4)
Author response: Regulation of the PI3K pathway through a p85α monomer–homodimer equilibrium (2015) (4)
Classification of Acute Myelogenous Leukemia (AML) Based on Patterns of Signal Transduction Pathway (STP) and Apoptosis Regulating Protein Activation Determined by Reverse Phase Proteins Arrays (RPPA). (2005) (4)
Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort (2017) (4)
A LINCS microenvironment perturbation resource for integrative assessment of ligand-mediated molecular and phenotypic responses (2021) (4)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response (2018) (4)
Inhibiting the IRE1α Axis of the Unfolded Protein Response Enhances the Antitumor Effect of AZD1775 in TP53 Mutant Ovarian Cancer (2022) (4)
Somatic Mutations of PIK 3 R 1 Promote Gliomagenesis (2012) (4)
Discussion: Metastasis and Angiogenesis in Epithelial Ovarian Cancer (2003) (4)
Clinical characteristics and survival outcomes in BRCA1-methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies. (2015) (4)
Local-Mass Preserving Prior Distributions for Nonparametric Bayesian Models (2014) (4)
Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature (2017) (4)
Systems Biology Approaches to Decoding the Genome of Liver Cancer (2011) (4)
Resistance to Endocrine Therapy in Estrogen Receptor-Positive (ER+) Breast Cancer Is Dependent upon Phosphatidylinositol-3 Kinase (PI3K) Signaling. (2009) (4)
Erratum to: Modeling precision treatment of breast cancer (2015) (4)
Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group Study. (1987) (4)
Definition of PKC-α , CDK 6 , and MET as therapeutic targets in triple-negative breast cancer (2014) (4)
Selective activity of dasatinib for the most common KIT mutation in melanoma (L576P). (2009) (4)
Immunogold Labeling of the Low‐Affinity (55 kd) IL2 Receptor on the Surface of IL2 Receptor‐Bearing Cultured Cells and Mitogen‐Activated Peripheral Blood Lymphocytes (1990) (4)
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance (2022) (4)
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer (2021) (4)
Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells (2013) (4)
RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy? (2014) (4)
Phosphorylation of ETS 1 by Src Family Kinases Prevents Its Recognition by the COP 1 Tumor Suppressor (2014) (4)
Abstract P4-08-05: Basement membrane localized tumor cells are protected from HER2-targeted therapy in vivo. (2012) (4)
Erratum: ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS (Proceedings of the National Academy of Sciences (2010) 107 (4153-4158) DOI: 10.1073/pnas.0913860107) (2012) (4)
Targeting gamma secretase: has progress moved up a Notch? (2018) (4)
Proteomics advances for precision therapy in ovarian cancer (2019) (3)
Chemo- and Radiosensitization Through Inhibition of PI3K/Akt Signaling (2007) (3)
Results of a high-throughput screen to identify compounds that modulate VHL proteostasis. (2012) (3)
PIE 2005: An intercomparison of measurement techniques for peroxyacyl nitrates (PANs) (2005) (3)
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance to the anti-EGFR monoclonal antibody cetuximab (2007) (3)
Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes. (2017) (3)
Chk 1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN 673 in gastric cancer (2017) (3)
Functional proteomic characterization of cancer cell lines (2017) (3)
Mutations and Prognosis in Breast Cancer Androgen Receptor Levels and Association with PIK 3 CA (2009) (3)
Lymphocyte function in human bone marrow. II. Characterization of an interleukin 2-sensitive T precursor-cell population (1985) (3)
Ascitic fluid from ovarian cancer patients contains a unique growth factor which stimulates ovarian cancer cells: Characterization, purification, and mechanism of action (1988) (3)
Abstract 5148: CanDrA: Cancer-specific driver missense mutation annotation with optimized features. (2013) (3)
Feasibility of real-time serial comprehensive tumor analytics: Pilot study of olaparib and durvalumab in metastatic triple negative breast cancer (mTNBC). (2020) (3)
Activation of the PI3K/AKT signal transduction pathway is inversely associated with estrogen receptor levels and correlates with survival in hormone receptor-positive Her2/neu-negative breast cancer (2007) (3)
L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary (2022) (3)
An epithelial-mesenchymal transition (EMT) gene signature to predict resistance to EGFR inhibition and AXL identification as a therapeutic target in head and neck squamous cell carcinoma. (2013) (3)
Reverse-phase protein array marker evaluation of protein expression patterns related to anti-angiogenesis treatment in renal cell carcinoma (2008) (3)
Correction: Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer (2019) (3)
Expression of CD 26 and Its Associated Dipeptidyl Peptidase IV Enzyme Activity Enhances Sensitivity to Doxorubicin-induced Cell Cycle Arrest at the G 2 / M Checkpoint 1 (2001) (3)
Abstract P4-06-01: Expression and DNA copy number profiling suggest novel therapeutic approaches for triple negative breast cancer subtypes (2013) (3)
Prostaglandins inhibit proliferation of the murine P815 mastocytoma by decreasing cytoplasmic free calcium levels [( Ca+2]i). (1988) (3)
Abstract 142: SiRNA therapy against novel lncRNA NRCP: shutting down the fuel for cancer cells (2015) (3)
Comparison of Breast CancerMolecular Features and Survival byAfrican and EuropeanAncestry in The Cancer GenomeAtlas (2017) (3)
Author Correction: Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer (2018) (3)
Abstract 3303: A comprehensive TCGA Pan-Cancer molecular study of gynecologic and breast cancers (2018) (3)
Abstract 4831: ATM signals to TSC2 in the cytoplasm to regulate mTORC1 and autophagy in response to ROS (2010) (3)
P5-21-01: A Renewable Tissue Resource of Phenotypically Stable Human Breast Cancer Xenografts for Preclinical Studies. (2011) (3)
Analysis of molecular aberrations in ovarian cancer allows novel target identification. (2004) (3)
An Integrated Clinical, Omic, and Image Atlas of an Evolving Metastatic Breast Cancer (2020) (3)
Therapeutics , Targets , and Chemical Biology Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER 2 Homodimers (2011) (3)
Gene Expression Signatures of PI3K Signaling Are Associated with Low ER Levels and the Luminal B Subtype in Breast Cancer Cell Lines and Human Tumors, and in Patients Predicts Poor Outcome. (2009) (3)
Anti-HER 2 Antibody and Heregulin Suppress Growth of HER 2-Overexpressing Human Breast Cancer Cells through Different Mechanisms 1 (2000) (3)
Impact of Cold Ischemic Time and Freeze-Thaw Cycles on RNA, DNA and Protein Quality in Colorectal Cancer Tissues Biobanking (2019) (3)
57 A functional genetic approach identifies the PI3K pathway as a major determinant of Trastuzumab resistance in breast cancer (2009) (3)
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers (2021) (3)
Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance (2021) (3)
Intratumoral focused chemotherapy with cisplatin/epinephrine injectable gel for palliative treatment of metastatic breast cancer (1998) (3)
Soft Tissue Sarcoma Cells Are Highly Sensitive to AKT Blockade: A Role for p53-Independent Up-regulation of GADD45A (2008) (3)
Identification of a subpopulation of reactive large granular mononuclear cells in allogeneic heart transplantation. (1993) (2)
Human hematopoietic cell express two forms of the cytokine receptor common gamma-chain (gamma c). (1997) (2)
Uncoupling of gene expression from copy number presents therapeutic opportunities in aneuploid cancers (2021) (2)
Characterization of the role Rab25 in energy metabolism and cancer using extracellular flux analysis and material balance. (2015) (2)
PTEN loss as a context-dependent determinant of patient outcomes in obese and non-obese endometrioid endometrial cancer patients. (2013) (2)
Basal-subtype and MEK-PI3K feedback signaling determine susceptibility of breast cancer cells to MEK inhibition (2008) (2)
OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets (2014) (2)
Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer (2014) (2)
Abstract 3268: Proteomic response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Reverse phase protein array (RPPA) results from NeoAva - a randomized phase II study (2016) (2)
Ultra-deep next-generation sequencing of plasma cell-free (cf) DNA from patients with advanced cancers. (2015) (2)
The roles of MAGEA6 variants in pancreatic cancer development and their potential impact on cancer immunotherapy (2020) (2)
Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. (2022) (2)
Expression of the tumor suppressor gene ARHI induces autophagic cell death in ovarian cancer cells (2005) (2)
General keynote: molecular therapeutics and pharmocogenomics. (2003) (2)
MODULATION OF AUTOPHAGY AND ITS POTENTIAL FOR CANCER THERAPY. (2011) (2)
Abstract 3072: miR-551b amplification regulates STAT3 expression and resistance to anoikis of ovarian cancer cells (2015) (2)
Therapeutic Target for Overcoming EGFR Inhibitor Resistance Resistance to EGFR and PI 3 K Inhibitors and Identifies Axl as a Mesenchymal Transition Gene Signature Predicts (2012) (2)
Identification of unique somatic mutations with functional relevance through genetic characterization of gallbladder cancer (GB ca). (2013) (2)
Abstract 856: High expression of DUSP4 in ER-negative breast cancer cells suppresses growth and invasion. (2013) (2)
Cadherin endocytosis (2009) (2)
Molecular Pathogenesis of Ovarian Cancer (2014) (2)
Program and abstracts for the 2012 Joint Meeting of the Society for Glycobiology & American Society for Matrix Biology (2012) (2)
Identification of selective inhibition of phospho-S6 ribosomal protein in XK469 sensitive leukemia cell lines using functional proteomic analysis (2005) (2)
Molecular Pathogenesis of Epithelial Ovarian Cancer (2008) (2)
TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors. (2021) (2)
Abstract 2969: Progress in The Cancer Genome Atlas bladder cancer project (2015) (2)
Mesenchymal Stem Cells Promote Survival of Leukemic Cells Via Integrin-Linked Kinase (ILK)-Dependent Akt and STAT3 Activation: Implications for Leukemia Therapy. (2004) (2)
PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer: Jensen JD, Laenkholm A-V, Knoop A, et al (Odense Univ Hosp, Denmark; Univ Hosp of Copenhagen, Denmark; et al) Clin Cancer Res 17:667-677, 2011§ (2011) (2)
Regulation of mRNA expression in breast cancer - a cis-tematic trans-action (2012) (2)
Abstract 272: Nanoscale high-throughput quantitative RT-PCR for the characterization of targeted-therapy related molecular biomarkers from recurrent and non-recurrent NSCLC tissues (2012) (2)
Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?” (2022) (2)
RAPID COMMUNICATION Activated Src Protein Tyrosine Kinase Is Overexpressed in Late-Stage Human Ovarian Cancers 1 (2003) (2)
Abstract S5-4: Synthetic-Lethality of Triple-Negative Breast Cancers Via the MYC Oncogene Pathway (2010) (2)
Abstract 4565: Whole exome sequencing links MAPK1 mutation to exquisite sensitivity to brief erlotinib monotherapy in head and neck cancer. (2013) (2)
ENPAC: phase II trial with safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinoma (2021) (2)
Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian Cancer (2011) (2)
Cancer Therapy : Preclinical Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo (2012) (2)
3-biomarker HRD score versus individual biomarker (LOH, TAI, LST) scores in platinum treated serous ovarian cancer (SOC) (2016) (2)
Cell growth regulation in ovarian cancer: tyrosine kinases, tyrosine phosphatases and tumour necrosis factor-α (1995) (2)
Bast (2021) (2)
Abstract 3955: Spatially resolved, multiplexed digital characterization of protein and mRNA distribution and abundance in formalin-fixed, paraffin-embedded (FFPE) tissue sections based on NanoString’s Digital Spatial Profiling (DSP) technology: applications to immuno-oncology (IO) and tumor heteroge (2017) (2)
Candidate biomarker assessment for pharmacological response (2020) (2)
BET inhibition induces an anti-apoptotic adaptive response and therapeutic vulnerability to MCL1 inhibitors in breast cancer (2019) (2)
Identifying Abundant Immunotherapy and Other Targets in Solid Tumors: Integrating RNA-seq and Mass Spectrometry Proteomics Data Sets. (2017) (2)
A functional genomic approach to actionable gene fusions for precision oncology (2022) (2)
PDK 1 potentiates upstream lesions on the PI 3 K pathway in breast carcinoma (2009) (2)
Erratum: Stem cell-ness: A "magic marker" for cancer (Journal of Clinical Investigation (2005) 115 (1463-1467) DOI: 10.1172/JCI25455) (2005) (2)
Erratum: Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis (The Journal of Biological Chemistry (2009) vol. 284 (7385-7394)) (2009) (2)
Systems biology of breast cancer (2009) (2)
Human hematopoietic cells express two forms of the cytokine receptor common γ-chain (γc) (1997) (2)
Erratum: Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis (Cancer Research (2010) 70, (3287-3298) DOI:10.1158/0008-5472. CAN-09-3467) (2010) (2)
Erratum: AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis (EMBO Reports (2012) 13 (554-560) DOI 10.1038/embor.2012.53) (2014) (2)
Overexpression of the Plasma Lysophospholipase D Autotaxin Reveals a Novel Pathway for Regulation of Hemostasis in Mice. (2007) (2)
Integrated quantative and spatial proteomic analysis of PI3kinase signaling in high grade prostate cancer (PCa) treated with Temsirolimus with or without androgen ablation (2008) (2)
BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators (2021) (2)
Abstract P1-07-06: Effect of biospecimen variables on proteomic biomarker assessment in breast cancer (2012) (2)
Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells (1990) (2)
Targeting ncRNAs in the 3q26.2 amplicon (2015) (2)
Abstract PR05: P-REX1 creates a positive feedback loop to activate growth factor receptor/PI3K signaling (2013) (2)
Stiff matrix induces exosome secretion to promote tumour growth (2023) (2)
Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic CTNNB1 mutation on recurrence-free survival (2022) (2)
Context-specificity in causal signaling networks revealed by phosphoprotein profiling (2016) (2)
Abstract 60: Mig-6 suppresses development and progression of endometrial cancer by inhibiting ERK2 phosphorylation (2014) (2)
Genomic alterations driving breast cancer (BC) metastases and their relationship with the subtype switch in the GEICAM ConvertHER study. (2017) (2)
Abstract 682: Increased stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients (2012) (2)
Abstract 5563: 3D Biology™ view of cancer: Simultaneous detection of somatic DNA mutations and expression profiling of genes and signaling proteins from melanoma tumor FFPE samples (2017) (1)
Comprehensive molecular profiling of urothelial bladder cancer at the DNA, RNA, and protein levels: A TCGA project. (2014) (1)
Molecular Diagnostics in Cancer (2017) (1)
Biomolecular Condensation: A New Phase in Cancer Research (2022) (1)
Prevention and early detection of ovarian cancer (2007) (1)
Differential Signaling by ErbB Receptor (HER) Dimers: Implications for Response to Anti-HER2 Therapies in Breast Cancer. (2009) (1)
Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies (2022) (1)
751 Correlation of copy number, gene and protein expression for breast cancer related genes and proteins (2010) (1)
High Throughput Proteomic Analysis of 559 Acute Myelogenous Leukemia (AML) Patient Samples on a Single Slide Using Reverse Phase Proteins Arrays (RPPA): Analysis of Signal Transduction Pathway (STP) and Apoptosis Regulating Proteins. (2006) (1)
1 Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trials (2014) (1)
Abstract AP31: ATR INHIBITION TARGETS TREATMENT RESISTANT OVARIAN CANCER (2019) (1)
Cancer Therapy : Preclinical Reciprocal Regulation of cSrc and STAT 3 in Non-Small Cell Lung Cancer (2009) (1)
Mechanical stress in pancreatic cancer: Signaling pathway adaptation activates cytoskeletal remodeling and enhances cell migration (2021) (1)
CHAPTER 6 – TRANSMEMBRANE SIGNALING BY INTERLEUKIN 2 (1988) (1)
AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic. (2020) (1)
Multidimensional spatial characterization of the tumor microenvironment (TME) in synchronous melanoma metastases (SMM) to yield insights into mixed responses to therapy in metastatic melanoma (MM) patients (pts). (2017) (1)
Correction: RCP induces Slug expression and cancer cell invasion by stabilizing β1 integrin (2019) (1)
8: Tumour molecular profiling and quantitative detection of circulating biomarkers in patients with lung cancer (2015) (1)
IMP1/IGF2BP1 in human colorectal cancer extracellular vesicles. (2022) (1)
Abstract 1371: Spatially-resolved, multiplexed digital characterization of protein distribution and abundance in FFPE tissue sections (2016) (1)
Different Mechanisms for Acquired Resistance to Trastuzumab and Lapatinib in HER2 Positive Breast Cancers: Role of ER and HER2 Reactivation. (2009) (1)
Differential Roles of PDK1 and Akt1 Expression and Phosphorylation in Breast Cancer Cell Resistance to Paclitaxel, Doxorubicin, and Gemcitabine Molecular (2006) (1)
Reverse Phase Protein Arrays: From Technical and Analytical Fundamentals to Applications (2019) (1)
A distinct pattern of growth and RAC1 signaling in melanoma brain metastasis cells (2022) (1)
with Phosphatidylinositol 3-Kinase Functional and Physical Interaction of EMT Family Tyrosine Kinase EMT/ITK/TSK: CD28 But Not CD3 Regulation of the TEC Phosphatidylinositol 3-Kinase Is Required for (1998) (1)
A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas (2021) (1)
Erratum: Lysophosphatidic acid production and action: Validated targets in cancer? (Journal of Cellular Biochemistry (2004) 92 (1115-1140)) (2004) (1)
The Genomic Landscape a nd Clinical Relevance of A-toI RNA Editing in Human Cancers Graphical (2015) (1)
Targeting Adaptation to Cancer Treatment by Drug Combinations (2021) (1)
Abstract 5398: TARDBP regulates glycolysis in hepatocellular carcinoma by regulating PFKP through miR-520. (2013) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
Abstract 3955:PIK3R1loss activates AKT and STAT3 signaling in ovarian cancer (2018) (1)
Abstract 312: Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis (2014) (1)
Abstract 4946: Control of cellular proliferation by ERK: A quantitative analysis in single cells (2012) (1)
Methylation and Messenger RNA Expression ofp15 but Not p16 Are Independent Risk Factors for Ovarian Cancer (2005) (1)
Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer. (2021) (1)
Abstract 4835: Targeting the ATR/CHK1 axis in combination with PARP inhibition is more effective than PARP inhibition alone in BRCA mutant models (2016) (1)
Modeling precision treatment of breast cancer (2013) (1)
Transgenic Expression of Mitochondrial Chaperone TRAP1 Accelerates Prostate Cancer Development (2016) (1)
Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors. (2013) (1)
Identi fi cation of Variant-Speci fi c Functions of PIK 3 CA by Rapid Phenotyping of Rare Mutations (2015) (1)
Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers (2019) (1)
Novel Therapeutic Approaches and Targets for Ovarian Cancer (2019) (1)
Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors. (2017) (1)
Molecular therapeutics in ovarian cancer (2003) (1)
Expression of p 53 in Cisplatin-resistant Ovarian Cancer Cell Lines : Modulation with the Novel Platinum Analogue ( 1 R , 2 R-Diaminocyclohexane ) ( trans-diacetato ) ( dichloro )-platinum ( IV ) 1 (1999) (1)
Abstract IA17: Delivering on the promise of personalized medicine (2016) (1)
Tyrosine phosphorylation and activation of the tec family kinase member emt/itk/tsk following CD28 and CD3 crosslinking (1994) (1)
Abstract 2441: NanoString 3D Biology™ technology: simultaneous digital counting of DNA, RNA and protein (2017) (1)
Abstract 4862: Autocrine secreted IL-6 and IL-8 play critical and non-redundant roles in basal-like breast cancer cell transformation and growthin vitroandin vivo (2012) (1)
Abstract 4836: Inhibition of PI3K/mTOR leads to adaptive resistance in extracellular matrix attached cancer cells (2012) (1)
Genome copy number abnormalities in ovarian cancer (2003) (1)
Therapeutics , Targets , and Chemical Biology ZNF 668 Functions as a Tumor Suppressor by Regulating p 53 Stability and Function in Breast Cancer (2011) (1)
Abstract 3541: Epigenetic regulation of KPC1 ubiquitin ligase has a regulatory role on the NF-κB pathway in metastatic melanoma (2018) (1)
Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers (2018) (1)
Abstract 5525: Induced expression of PPM1A in ER-negative breast cancer cells inhibits growth by suppressing CDK phosphorylation (2017) (1)
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers (2022) (1)
Expression of Functional Interleukin 2 Receptors in Burn Patients May Be Regulated by Interleukin 3 (1989) (1)
Which path to follow? Utilizing proteomics to improve therapy choices for breast cancer patients (2020) (1)
Time Course Proteomic Profiling of Signal Transduction and Apoptosis Pathways in AML Survivor Cells Using Reverse Phase Protein Lysate Microarray (RPPA) Reveals Differential Effect of Time, Dose and Agent(s). (2005) (1)
The impact of adjuvant treatment in intermediate risk, Stage I endometrial cancer with somatic CTNNB1 mutation (2019) (1)
Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer (2013) (1)
Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy (2012) (1)
The relationship between response and dose in published, contemporary phase 1 oncology trials. (2019) (1)
Expression of Concern: Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer (2020) (1)
Abstract 2011: The PI3K pathway is the most frequently mutated mitogenic pathway in HNSCC. (2013) (1)
Abstract 3603: Identification of potential pharmacodynamic markers for HER3 targeted cancer treatment by a multi-technology approach (2012) (1)
Abstract A105: Androgen regulation of 5α-reductase isoenzymes in prostate cancer: Implications for prostate cancer prevention (2010) (1)
Higher order relationships and the Medicinal Algorithmic Combinatorial Screen (MACS) (2005) (1)
Abstract LB-231: Phase Ib dose escalation and biomarker study of MK2206 in combination with standard doses of weekly paclitaxel in patients with locally advanced or metastatic solid tumors with expansion in advanced breast cancer (2012) (1)
Genome-Wide Profiling of Acquired Uniparental Disomy Reveals Prognostic Factors in Head and Neck Squamous Cell Carcinoma (2019) (1)
Quantitative assessment of AKT activation in melanoma. (2009) (1)
Abstract 4396: MicroRNA MIR551B amplified at 3q26.2 locus activate c-KIT expression and causes resistance to anoikis of ovarian cancer cells (2014) (1)
Inihibition of PI3K by LY294002 promotes apoptosis and dephosphorylates bad in myeloid leukemias (2000) (1)
3 INVITED Challenges to Implementation of Personalised Cancer Therapy (2011) (1)
PMCA inhibition reverses drug resistance in clinically refractory cancer patient-derived models (2023) (1)
Expression and Activity of Both IGF and Insulin Signaling Pathways in a Large Panel of Breast Cancer Cell Lines. (2009) (1)
OMICS AND PROGNSTIC MARKERS (2013) (1)
Abstract 2070: Exploration of markers of synergistic lethality of PARP and PI3K-Akt-mTOR inhibitors in women's cancers (2019) (1)
Development of novel immunotherapy based on nanoparticle co-delivering PLK1 and PD-L1 inhibitors for lung cancer treatment (2021) (1)
The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression (2019) (1)
Abstract 971: Phosphatase PTP4A3 is critical for cell growth of triple-negative breast cancer (2014) (1)
Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors. (2017) (1)
Frequent post-treatment monitoring of colorectal cancer using individualized ctDNA validated by multi-regional molecular profiling (2020) (1)
Early detection of cancer. (2008) (1)
p85α neomorphic mutants: splitting away from the canonical path (2015) (1)
Regulation of mRNA expression in breast cancer - a cis-tematic trans-action (2012) (1)
Artesunate decreases invasion of non-small cell lung cancer (2008) (1)
Suppression of p16 increases nucleotide synthesis via mTORC1 (2018) (1)
Abstract CT-03: Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer (2012) (1)
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase (2014) (1)
Multiomics profiling of longitudinal melanoma specimens unravels molecular mechanisms of resistance to sequential targeted and cancer immunotherapies. (2020) (1)
Metastasis and angiogenesis in epithelial ovarian cancer (2003) (1)
Panobinostat Induced Spatial In Situ Biomarkers Predictive of Anti-PD-1 Efficacy in Mouse Mammary Carcinoma (2023) (1)
331: Integrative analysis reveals extensive association between microRNA expression and mRNA–protein translation (2014) (1)
Whole-chromosome arm acquired uniparental disomy in cancer development is a consequence of isochromosome formation (2022) (1)
Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA (2020) (1)
Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations (2020) (1)
Modulation of breast cancer cell-free DNA with surgical resection. (2013) (1)
Abstract 356: Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer (2011) (1)
Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets (2022) (1)
Multiplex spatial systems analysis of local nanodose drug responses predicts effective treatment combinations of immunotherapies and targeted agents in mammary carcinoma (2021) (1)
Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma (2020) (1)
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation (2014) (1)
Molecular Medicine in Practice PI 3 K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer (2011) (1)
Abstract 3116: Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in ovarian cancer (2012) (1)
LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer (2013) (1)
Abstract #3822: PDK1-SGK3 signaling in the absence of AKT activation in PIK3CA- mutant cancers (2009) (1)
Abstract PD01-01: Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors (2012) (1)
Abstract P5-06-01: MTA2 and AR Overexpression in ER-Negative Breast Cancer Cells: Roles in Invasion and Metastasis (2010) (0)
Abstract 2706: Effects of germline and somatic mutations on protein expression in tumor and adjacent normal tissues in breast, ovarian, and colorectal tumors (2018) (0)
Abstract 2329: DAPK-1, a death signaling transducer, is critical for the tumorigenicity of p53 mutant breast cancer. (2013) (0)
Phase 1b dose expansion and translational analyses of olaparib in combination with the oral AKT inhibitor capivasertib in recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer (2021) (0)
Abstract 4276: T200: a high depth targeted exome sequencing platform to identify actionable alterations in FFPE solid tumor samples (2014) (0)
Abstract 1306: Density-based mutation clustering in 3D space (2018) (0)
Visentin Supplemental data (2014) (0)
Correction: Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. (2020) (0)
Abstract 4260: PTPRT mutation induces STAT3 activation in HNSCC preclinical models. (2013) (0)
488 Development of a publicly accessible knowledgebase to facilitate decision support for clinical cancer genomics reporting (2014) (0)
Abstract 3843: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models (2016) (0)
Breast cancer quantitative proteome and proteogenomic landscape (2019) (0)
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. (2012) (0)
P5-01-05: Activating Mutations in PIK3CA or AKT1 in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). (2011) (0)
Relationship between differences in RNA or protein expression and the effects of race/ethnicity on breast cancer outcomes. (2011) (0)
Reply to M.P. Decatris et al. (2016) (0)
Oncogenic ras predicts lack of response to PX-866, an inhibitor of the phosphatidylinositol-3-kinase pathway in tumor xenograft models. (2007) (0)
Abstract A39: Patient-derived xenografts to test emerging therapies for triple negative breast cancer (2016) (0)
Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer (2017) (0)
Abstract 1982: Analyzing TCGA data: A novel, systems-oriented method for diagnosing batch effects and adjusting for them (2010) (0)
Association of gene copy number alterations in formalin-fixed, paraffin-embedded tumors with prognostic molecular and pathologic tumor subtypes in early-stage breast cancer. (2010) (0)
Genomic technologies in cancer research, drug discovery and development (2002) (0)
Selective abrogation of S6K2 maps lipid homeostasis as a survival vulnerability in MAPKi-resistant NRASMUT melanoma (2021) (0)
Abstract LB-37: P-REX1 is a novel PTEN-interacting protein that activates PI3K signaling in breast cancer. (2013) (0)
Investigation of ethnic differences in the prevalence of chromosomal number aberrations of luminal and triple-negative breast cancers associated with risk of recurrence. (2010) (0)
Abstract MIP-060: EPIGENETIC DYSREGULATION OF A HISTONE MARK REVEALS A METABOLIC VULNERABILITY IN OVARIAN CANCER (2017) (0)
Abstract 3298: High-content phenotyping of somatic cancer mutations by functional variomics (2018) (0)
Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype (2018) (0)
Abstract POSTER-THER-1431: Combined Src and MEK inhibition decreases ovarian cancer (OVCA) cell growth, tumorigenicity and aldehyde dehydrogenase positive tumor-initiating-cells (2015) (0)
Abstract 2282: The K303R estrogen receptor α mutation and hormone resistance in breast cancer (2011) (0)
Retraction Note to: The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells (2021) (0)
- Emt: Expressed mainly in T cells (vertebrates) (Itk, Tsk) (1995) (0)
Ovarian Cancer Models in Vivo and in Vitro of Paclitaxel in-Kinase Increases Efficacy ′ Inhibition of Phosphatidylinositol 3 Updated (2002) (0)
Abstract PD8-11: APOBEC3 contributes to mutational load in breast cancer (2018) (0)
High risk CNIs, race and early stage breast cancer (2013) (0)
Erratum: Tyrosine phosphorylation is obligatory event in IL-2 secretion (Journal of Immunology (October 1, 1990) 7 (2189)) (1991) (0)
Abstract A42: Autocrine-produced IL-6 and IL-8 are essential for the growth and maintenance of the transformed phenotype of basal-like breast cancer cells (2011) (0)
Abstract 2229: Molecular profile of histological and mutational heterogeneity of adenocarcinoma of the stomach in tumor burden monitoring using circulating tumor DNA (2019) (0)
Mediated Mouse Mammary Tumors − Brca 1 / p 53 Cancer Stem Cells Contribute to Cisplatin Resistance in Updated (2008) (0)
Abstract 4736: ADAMs: potential biomarkers and oncotargets in breast cancer (2017) (0)
Correction: Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines (2013) (0)
Epithelial-mesenchymal transition confers resistance to rapamycin (2011) (0)
Abstract 1018: Structural features of novel dimeric quinacrines that have single-agent antitumor activity determine the mechanism of action: destabilization of mTORC1/lysosomal interaction versus DNA damage (2016) (0)
Abstract CT188: Pharmacodynamic changes by durvalumab in combination with chemotherapy in women with untreated, advanced stage ovarian cancer (2020) (0)
Abstract 4211: The proteomic characterization of HNSCC patient-derived xenografts (2015) (0)
Role of systems biology in chemoprevention drug identification and implementation (2007) (0)
Abstract C199: Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. (2013) (0)
2 p 57 Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor Akt and ERK Control the Proliferative Response of Mammary Epithelial (2012) (0)
567 A rationale for anti-angiogenic therapy in head and neck cancer (2010) (0)
Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance. (2013) (0)
Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust (vol 39, pg 1818, 2003) (2004) (0)
Lactate dehydrogenase B in breast cancer contributes to glycolytic phenotype and predicts response to neoadjuvant chemotherapy (2012) (0)
Abstract P4-06-04: Triple negative breast cancer patient-derived xenografts: Molecular characteristics and sensitivity to emerging therapies (2017) (0)
Abstract 2976: Intratumoral cellular heterogeneity of epithelial ovarian carcinoma and its impact on tumor behavior (2014) (0)
Abstract P3-04-01: Molecular determinants of post-mastectomy breast cancer recurrence (2018) (0)
Abstract PR03: The Hippo pathway effector YAP1 contributes to escape from proliferation arrest under chronic PI3K/mTOR inhibition (2015) (0)
Abstract C163: Gene expression signature‐based Connectivity Map analysis revealed vorinostat as a novel therapeutic target agent in human gastric cancer (2009) (0)
- Ttk: Threonine, tyrosine kinase (vertebrates) (1995) (0)
Abstract PD1-9: P-REX1 employs a positive feedback loop to activate growth factor receptor/PI3K signaling (2013) (0)
Abstract B48: Design of effective combination therapies for high-grade serous ovarian cancer using patient-derived xenograft models. (2016) (0)
Abstract LB-228: Resistance to BRAF inhibition in BRAF V600E colorectal cancer is associated with PI3K/AKT activation and hypermethylation (2011) (0)
Abstract 1702: Metabolic heterogeneity of HER2-positive breast cancers. (2013) (0)
Abstract 82: Novel role of DAPK-1 in growth regulation of ER-negative breast cancer (2012) (0)
A Systems Approach toAnalysis of Molecular Complexity in Breast Cancer 55 (2009) (0)
P-146 Higher order relationships and the medicinal algorithmic combinatorial screen (MACS) (2005) (0)
Abstract 1646: Beyond BRCA: Discovery of novel drivers of homologous recombination deficiencies in cancer (2019) (0)
Abstract PR06: A co-clinical assessment of patterns of BRAF inhibitor resistance (2015) (0)
Integrated transcriptomic–genomic tool Texomer profiles cancer tissues (2019) (0)
Abstract 2857: Induced expression of DUSP4 and PPM1A in ER-negative breast cancer cells suppresses proliferation and invasion (2012) (0)
Abstract 1065: Comprehensive molecular and experimental characterization of ovarian clear cell carcinoma cell lines forin vivodrug development (2019) (0)
Abstract 2702: Effects of Src and IGF1R inhibition on acquired endocrine therapy resistant breast cancer (2012) (0)
Abstract 5279: Induced expression of PPM1A in ER-negative breast cancer cells inhibits growth by suppressing cell cycle (2014) (0)
Abstract P5-10-03: OncomiR-569 deregulate p53 pathway and initiate breast oncogenesis (2012) (0)
Abstract 1971: BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer (2016) (0)
Abstract P6-06-01: Studies on tumor heterogeneity using a preclinical model of breast cancer caused by genetic alteration of the ATX-LPA axis (2015) (0)
Abstract A09: Rational combinational therapy with PARP and BRD4 inhibitor in ovarian cancer (2018) (0)
Abstract A02: Integrative analysis identifies differential miRNA expression in HPV-positive head and neck squamous cell carcinoma including mir-9 overexpression and corresponding downregulation of the target YAP1 (2015) (0)
Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer (2022) (0)
P2-03-04: Novel Pathways Underlying the Initiation and Transition of DCIS to IDC of HER2−Overexpressing Breast Cancer Model. (2011) (0)
969 CHARACTERIZATION OF IL2-DEPENDENT MARROW T PRECURSOR CELLS (1985) (0)
Rab25 augments cancer cell invasiveness through a β1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin (2018) (0)
A Fresh Approach to Identification and Characterization of Early Changes of Disease Associated with Ovarian Cancer (2011) (0)
Abstract 4040: Transcription factor Snail mediates EMT by altering vesicular trafficking protein Rab25 (2015) (0)
BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer (2020) (0)
Abstract GMM-036: COMPREHENSIVE GENOMIC, PROTEOMIC, AND EXPERIMENTAL CHARACTERIZATION OF OVARIAN CLEAR CELL CARCINOMA CELL LINES FOR IMPROVED DRUG DEVELOPMENT (2019) (0)
638 Acquired resistance to EGF receptor-targeted cancer therapy (2004) (0)
Abstract 162: Biomarker identification of residual triple negative breast cancer (TNBC) after standard neoadjuvant chemotherapy (NCT) (2012) (0)
Abstract 2842: Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models of melanoma identify c-Met as an effective second line combination therapy target (2015) (0)
Abstract PR06: Functional prioritization of rare gene aberration drivers of cancer (2015) (0)
Systems approach to personalized molecular medicine. (2009) (0)
Abstract 128: Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project (2016) (0)
Abstract 2979: A web portal of ‘next-generation’ clustered heat maps for user-friendly, interactive exploration of patterns in TCGA data (2015) (0)
Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect. (2015) (0)
Phosphoproteomics and mass-action modeling to predict optimal drug combination in signaling networks (2010) (0)
Functional interaction of the SHP1 SH2 domain containing tyrosine phosphatase with the PTEN tumor suppressor gene is regulated by growth factors (2000) (0)
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation (2019) (0)
Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC) (2013) (0)
Prospecting whole cancer genomes (2020) (0)
Abstract 135: Integrated analysis of cell signaling pathway-associated miRNAs using protein expression array data in NCI-60 cells (2012) (0)
Abstract 4291: p85α alters Gab2 phosphorylation profile in ovarian cancer (2019) (0)
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory (2019) (0)
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer (2015) (0)
Development and validation of an ultra-deep next-generation sequencing assay for 1 testing of plasma cell-free DNA from patients with advanced cancer 2 (2017) (0)
Abstract 1026: Identify BRD4 as a facilitator of replication stress response signaling (2017) (0)
TARDBP regulates glycolysis in hepatocellular carcinoma by regulating PFKP through (2013) (0)
A Single Nucleotide Polymorphism in the Matrix Metalloproteinase-1 Promoter Enhances Lung Cancer Susceptibility 1 (2001) (0)
1 mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV 39 H 1 in BRCA-proficient triple-negative breast cancer (2015) (0)
Abstract LB-272: Functional genomic analysis in cancer personalized therapy (2011) (0)
HER2 antibodies pertuzumab and trastuzumab differ in their effect on cell signaling and growth inhibition in breast cancer cells (2006) (0)
the of cancer and proteomic data across tumor types. (2016) (0)
Abstract 4127:EGFR and K-Rasmutations and resistance of lung cancer to the IGF-1R tyrosine kinase inhibitors (2010) (0)
Lysophosphatidic acid-induced amphiregulin secretion by cancer associated fibroblasts augments cancer cell invasion. (2022) (0)
273 Tissue lysate arrays as a cell based assay for validation of signal transduction inhibitors (2004) (0)
Abstract NT-098: WINDOW OF OPPORTUNITY TRIAL: ASSESSING THE ADAPTIVE RESPONSE OF HGSOC TO PARPI FOR INFORMED COMBINATION THERAPIES (2019) (0)
Abstract B44: Early loss of monoubiquitylation of H2B alters key metabolic and immune signaling pathways promoting the progression of high-grade serous ovarian cancer (2018) (0)
Abstract 1996: Identification of four subgroups of Triple Negative Breast Cancer (TNBC) by genomic profiling. (2013) (0)
CSIG-08NITROSOUREAS IMPROVE SURVIVAL IN THE SECONDARY-LIKE AKT SUBTYPE OF GLIOBLASTOMA (2015) (0)
Abstract 4275: Identifying cancer driver mutations in clinical sequencing data (2014) (0)
Homologous Recombination Deficiency and PARP Inhibition in Ovarian Cancer (2017) (0)
768 Peroxiredoxin-1 Protects Against Oncogene-induced Suppression of the Estrogen Receptor and is a Biomarker of Favourable Prognosis in Estrogen Receptor-positive Breast Cancer (2012) (0)
Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response (2017) (0)
TITLE-Characterization of a naturally occurring breast cancer subset enriched in EMT and stem cell characteristics Running title-Metaplastic breast cancer characterization (2009) (0)
Biology of Human Tumors In fl uence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer (2014) (0)
358 Proteomic pattern analysis serum for early detection of ovarian cancer (2003) (0)
388 An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors (2014) (0)
Abstract B197: Selective depletion of YAP1 with next-generation antisense oligonucleotides leads to immune cell infiltration and tumor regression in mouse models of HCC (2018) (0)
Cancer esearch rated Systems and Technologies : Mathematical Oncology tification of Optimal Drug Combinations Targeting lular Networks : Integrating Phospho-Proteomics R Computational Network Analysis (2010) (0)
Abstract 4646: Evaluation of EGFR gene amplification status, mRNA, protein, and phosphoprotein levels expression in head and neck cancer patient tissues (2010) (0)
Abstract B09: Selective depletion of YAP1 with next-generation (constrained ethyl-cEt) antisense oligonucleotides results in tumor regression in mouse models of HCC with YAP1 activation (2020) (0)
Abstract 3299: Maternal embryonic leucine zipper kinase is critical for the growth and migration of triple negative breast cancer cells (2014) (0)
Abstract 987: Comprehensive characterization of urothelial bladder cancer: a TCGA Project update (2014) (0)
elerates Mammary Tumorigenesis (2010) (0)
Interleukin 2 rapidly increases intracellular pH in interleukin 2-sensitive cells (1985) (0)
Molecular targets for epithelial ovarian cancer (2015) (0)
Additional file 1: of Comprehensive characterization of circular RNAs in ~â1000 human cancer cell lines (2019) (0)
Abstract 1006: TP53-induced glycolysis and apoptosis regulator (TIGAR) induces NADPH production and growth in nasopharyngeal carcinoma cells (2011) (0)
Applications of Proteomics to Clinical Questions in Breast Cancer (2006) (0)
Abstract B40: Transcription factor Snail mediates EMT by altering vesicular trafficking protein Rab25 (2016) (0)
Mutation and functional analysis of PIK3CA and PIK3R1 in endometrial cancer (2011) (0)
Imaging , Diagnosis , Prognosis Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer (2011) (0)
Messenger RNA expression and methylation of selected tumor- suppressor genes predict increased risk of ovarian cancer (2008) (0)
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer (2012) (0)
Abstract LB-217: Microenvironment mediated mechanisms of resistance to HER2 inhibitors differ between HER2+ breast cancer subtypes (2017) (0)
A systems approach to identification and validation of biomarkers (2010) (0)
Abstract 903: Evaluation of predictive biomarkers and resistance mechanisms of PI3K pathway inhibition in head and neck squamous cell carcinoma (2014) (0)
Perifosine accumulates preferentially in tumor tissues: Correlation between intratumoral accumulation and inhibition of cell proliferation and tumor growth (2007) (0)
Understanding the Functions of Lysophosphatidic Acid Receptors in Cancer (2013) (0)
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors (2014) (0)
Abstract AS31: MEK inhibition reverses antiestrogen resistance in ovarian cancer (OVCA) via alteration of cell cycle pathways and MAPK/estrogen regulated gene expression (2015) (0)
Peripheral T Cells Receptor-Induced Apoptosis of Activated Tyrosine Phosphatase-1 Inhibits Antigen The Src-Homology Domain 2-Bearing Protein (1999) (0)
An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays (2012) (0)
Therapeutics , Targets , and Chemical Biology De fi nition of PKC-a , CDK 6 , and MET as Therapeutic Targets in Triple-Negative Breast Cancer (2014) (0)
Ovarian Cancer α Growth-Regulated Oncogene Lysophosphatidic Acid Is a Major Regulator of Updated (2006) (0)
Abstract PR01: Systems analysis of signaling pathway adaptation to design effective PI3K-based combination therapies using ovarian cancer patient-derived xenografts (2017) (0)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade (2018) (0)
Abstract 3957: Characterization of functional heterogeneity andin vivodynamics of clonal cell populations derived from the triple-negative breast cancer cell line MDA-MB-468 (2017) (0)
Abstract PR04: DNA-PK inhibition resensitizes ovarian cancer cells to cisplatin in vivo and is associated with modulation of AKT pathway signaling (2013) (0)
Abstract 683: Evaluation of PTEN and PIK3CA status in breast cancer for patient selection: Cross-validation between institutions (2012) (0)
Effect of lysophospholipids on signaling in the Human jurkat T Cell Line (2005) (0)
10th Biennial Helene Harris Memorial Trust meeting. (2006) (0)
Abstract 2357: Utilizing biological and protein structure-guided features to improve driver mutation discovery (2018) (0)
Characterizing Intratumoral Heterogeneity : A Role for Cell Plasticity (2016) (0)
Integrated Systems and Technologies Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing (2013) (0)
Erratum to “Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust” [European Journal of Cancer, 39 (2003) 1818–1827] (2004) (0)
Clinical utilization of precision oncology decision support for genomically-informed cancer therapy. (2016) (0)
Erratum to: Modeling precision treatment of breast cancer (2015) (0)
Abstract 3579: Identification of biomarkers of AXL-mediated drug resistance in head and neck squamous cell carcinoma (2015) (0)
Abstract A12: High-throughput mutation analysis of NSCLC circulating tumor cells (2012) (0)
Ovarian cancer grows intraperitoneally due to growth factors present in ascitic fluid: Development of animal model systems and methods to block ascitic fluid growth factor activity (1989) (0)
Abstract 3052: Targeting AXL inPIK3R2-amplified ovarian cancer (2020) (0)
Agents that Stabilize Mutated von Hippel Lindau Protein Result in Differential Post-Translational Modification and Subcellular Localization : Results of a High Throughput Screen to Identify Compounds that Modulate VHL (2014) (0)
Original Article Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis (2010) (0)
Abstract IA13: Systems approach to drug development (2018) (0)
Correction to: Hormonal modulation of ESR1 mutant metastasis (2021) (0)
Abstract 2853: Discovery of phosphatases that regulate growth and tumorigenicity of ER-negative breast cancers (2012) (0)
Systems biology approach to the discovery and implementation of targeted therapeutics (2008) (0)
PI3-kinases and cancer (2008) (0)
158 INVITED Introductory talk (broad overview multiple approaches) (2007) (0)
108 INVITED Preclinical and clinical studies (2007) (0)
Systems approach to drug development and implementation (2008) (0)
608 Systems approach to personalized molecular medicine (2010) (0)
AKT-independent, PDK1-dependent signaling by oncogenic PIK3CA mutations (2008) (0)
340 Delivering on the promise of personalized medicines (2010) (0)
Abstract 2218: Systematic identification of combinatorial markers of drug sensitivity in cancer cell lines. (2013) (0)
Genome Scanning and Gene Discovery in Breast and Ovarian Cancer (1998) (0)
Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas (2018) (0)
Genetic changes in connection with cancer (1998) (0)
Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis (2018) (0)
4373 Defining the role of non-canonical PIK3CA mutations in head and neck squamous cell carcinoma (2020) (0)
Integrated genomic characterization of oesophageal carcinoma (2017) (0)
Author Correction: Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis (2019) (0)
Journalistic and other Media Writing Guides (1978) (0)
068 Isolation of a possible human counterpart to the murine XLR genes (1992) (0)
Prognostic relevance of acquired uniparental disomy in serous ovarian cancer (2015) (0)
Dermatology Research (2018) (0)
The development of an efficient procedure for protein extraction from formalin fixed and paraffin embedded tissues and analysis of its application to reverse phase protein arrays (2010) (0)
19 INVITED “Integrative epidemiology” - from risk assessment to outcome prediction (2006) (0)
Abstract 1123: OncomiR-569 hit p53 pathway and deregulate proliferation of ovarian epithelial cells. (2013) (0)
ComprehensiveGenomicAnalysis IdentifiesNovel Subtypes and Targets of Triple-Negative Breast Cancer (2015) (0)
Personalized Integrated Network Modeling of the Cancer Proteome Atlas (2018) (0)
Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro (2018) (0)
Comprehensive assessment of computational algorithms in predicting cancer driver mutations (2020) (0)
p85β regulates autophagic degradation of AXL to activate oncogenic signaling (2020) (0)
PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis (2020) (0)
Comprehensive characterization of circular RNAs in ~ 1000 human cancer cell lines (2019) (0)
Systematic Pan-cancer Functional Inference and Validation of Hyper, Hypo and Neomorphic Mutations (2023) (0)
MULTIPLATFORM ANALYSIS OF INTRATUMORAL PTEN HETEROGENEITY IN MELANOMA. (2023) (0)
contributes to myeloid cell growth G-CSF induced reactive oxygen species involves Lyn-PI 3-kinase-Akt and (2013) (0)
Abstract 2149: Biomarker-driven selection of polyADP ribose polymerase inhibitors (PARPi)-based combination therapies in patients with metastatic triple negative breast cancer (mTNBC) (2022) (0)
Supervised learning of high-confidence phenotypic subpopulations from single-cell data (2023) (0)
Abstract 5610: [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor drug-target engagement as a biomarker of response in ovarian cancer (2023) (0)
PharmacodynamicMarkers of Perifosine Efficacy (2007) (0)
WEE WIN: Window of opportunity study of induction WEE1 inhibition in advanced high-grade serous ovarian cancer. (2016) (0)
BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors (2023) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
The Breast Cancer Proteome and Precision Oncology. (2023) (0)
Sex-associated molecular differences for cancer immunotherapy (2020) (0)
Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer (2019) (0)
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers (2022) (0)
The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism (2016) (0)
Abstract PO-094: Glutaminase inhibition increases ionizing radiation induced oxidative stress and DNA damage in head and neck squamous cell carcinoma models (2021) (0)
A Novel Mouse Model that Recapitulates the Heterogeneity of Human Triple Negative Breast Cancer (2022) (0)
Abstract 3445: Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy (2023) (0)
Abstract B131: A prioritization pipeline for functionally annotating oncogenic somatic driver aberrations in cancer. (2013) (0)
Selective enrichment of plasma cell-free messenger RNA in cancer-associated extracellular vesicles (2022) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
RPPA SPACE: an R package for normalization and quantitation of Reverse-Phase Protein Array data (2022) (0)
Multiplex digital spatial profiling of proteins and RNA in fixed tissue (2020) (0)
Precision oncology for breast cancer through clinical trials (2021) (0)
Beyond BRCA: Discovery of novel causes and consequences of homologous recombination deficiencies (2022) (0)
Clinical Applications of Systems Biology Approaches (2011) (0)
Abstract 4916: Spatial analysis of local drug induced changes in tumor microenvironment predicts effective treatment combinations in breast cancer (2023) (0)
In Vivo Functional Characterization of EGFR Variants Identifies Novel Drivers of Glioblastoma. (2022) (0)
A window of opportunity trial for metastatic (WOO-M) pancreatic ductal adenocarcinoma (PDAC): A biomarker discovery platform. (2023) (0)
Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis (2022) (0)
Design of a protein signature predicting response to neo-adjuvant treatment with chemotherapy combined with bevacizumab in breast cancer patients. (2019) (0)
Comparison of genomic instability (GI) scores for predicting PARP activity in ovarian cancer (2020) (0)
Combination of Ionizing Radiation with Glutaminase Inhibition Improves Treatment Response in Head and Neck Squamous Cell Carcinoma (2019) (0)
The impact of adjuvant treatment in intermediate risk, stage I endometrial cancer with somatic mutation (2019) (0)
Abstract GMM-060: A NOVEL TREATMENT APPROACH FOR TARGETING CYCLIN E OVER-EXPRESSING OVARIAN CANCERS (2019) (0)
Detection of Serum Lysophosphatidic Acids Using Affinity Binding and Surface Enhanced Laser Desorption/Ionization (SELDI) Time of Flight Mass Spectrometry (2005) (0)
Abstract 2841: A co-clinical assessment of patterns of BRAF inhibitor resistance (2015) (0)
[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a pilot study. (2022) (0)
Abstract 1813: Bevacizumab potentiates the proteomic response to neoadjuvant chemotherapy in breast cancer patients: Rppa exploration of consecutive tumor samples in the NeoAva randomized phase II trial (2017) (0)
Abstract LB010: SMMART Program: A multi-omics tumor board with a focus on breast cancer (2021) (0)
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer (2020) (0)
Safety of bevacizumab in patients with glioblastoma multiforme ( GBM ) : a single institution ’ s experience (2011) (0)
Tumor Therapy: In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response (Adv. Mater. 31/2021) (2021) (0)
Multi-omics characterization of silent and productive HPV integration in cervical cancer (2023) (0)
Abstract OT3-05-01: Adaptive Multi-Drug Treatment of Evolving Cancers (AMTEC): A Phase II, Open-Label, Study of Olaparib in Combination with either Durvalumab, Selumetinib or Capivasertib, or Ceralasertib Monotherapy in Patients with Metastatic TNBC (2023) (0)
Abstract 3455: Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance (2023) (0)
The putative tumor suppressor WWOX protein is normally expressed in surface ovarian epithelium and frequently lost in ovarian carcinomas (2004) (0)
Ongoing Replication Stress Response and New Clonal T Cell Development Discriminate Between Liver and Lung Recurrence Sites and Patient Outcomes in Pancreatic Ductal Adenocarcinoma (2022) (0)
Abstract 5627: Spatial protein profiling by cyclic immunofluorescence to interpret and improve bulk tumor-based predictor of response to chemotherapy with bevacizumab in neoadjuvant breast cancer treatment (2023) (0)
Abstract LB178: Cell free RNA for prediction of PDAC in de novo symptomatic patients presenting for EUS-FNA (2023) (0)
Modeling heterogeneity of Triple-Negative Breast Cancer highlights potency of WEE1 and BCL-XL targeting (2020) (0)
Spatial oriented single-cell proteomic assay of low grade serous ovarian carcinoma identifies tumor oncogenic pathways associated with brain metastases (233) (2022) (0)
Abstract 5641: Single cell spatial molecular imaging of 76-plex proteins in clinical cancer samples in response to personalized treatment (2023) (0)
Abstract 2153: Cyclin E1 protein overexpression sensitizes ovarian cancer cells to ZN-c3, a novel, selective and oral bioavailable inhibitor of Wee1 (2023) (0)
Systematic identification of synergistic combinations of targeted agents and immunotherapies in breast cancer using intratumor multiplex implantable microdevice assay (2021) (0)
Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening (2017) (0)
Abstract 4133: Comparative gene expression and proteomic analysis of IGF-I and insulin signaling in a large panel of breast cancer cell lines (2010) (0)
Su113 IMP1 ENHANCES EXTRACELLULAR VESICLE PRODUCTION IN COLON CANCER VIA THE ENDOSOMAL PATHWAY (2021) (0)
Tumor Suppressor ARID1A Deficiency Impairs DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors (2018) (0)
Results Reduction in Autotaxin / Lysophospholipase D Levels Promotes Hypoxia-Induced Pulmonary Remodeling in Mice (2011) (0)
Abstract PR13: Investigating the importance of low allele frequency mutations for cancer patient management (2015) (0)
IMP1 Enhances Extracellular Vesicle Secretion in a Transformation‐Dependent Manner (2021) (0)
Abstract 2448: mTOR inhibitor MLN0128 Has antitumor efficacy in cell lines with intrinsic and acquired rapamycin resistancein vitroandin vivo. (2013) (0)
Abstract 1379: High throughput screening to identify molecules that alter VHL stability (2011) (0)
Metabolic , Endocrine and Genitourinary Pathobiology PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C 57 BL / 6 Mice via mTOR-Dependent Growth (2010) (0)
Abstract 4929: Leveraging multi-omics tumor boards for precision medicine in the OHSU SMMART Treatments Program (2019) (0)
Author Correction: Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer (2018) (0)
Abstract P5-13-05: Multiplex spatial systems analysis of responses to spatially separate nanoliter doses of drug predicts systemic immune-modulating combination treatments in breast cancer (2022) (0)
Abstract. Tolerance of glucose deprivation is an important factor for cancer proliferation, survival, migration and progression. To systematically understand adaptive responses under glucose starvation in cancers, we analyzed reverse phase protein array (RPPA) data of 115 protein antibodies across a (2015) (0)
Abstract 1186: Patient-derived breast cancer xenografts demonstrate molecular evolution in the phosphatidylinositol 3-kinase pathway upon engraftment (2014) (0)
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer (2017) (0)
Author Correction: Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis (2019) (0)
Abstract 1412: Comprehensive characterization of clock genes in human cancers (2018) (0)
Author response: Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy (2015) (0)
Molecular Mechanisms of Pathogenesis and Progression of Epithelial Ovarian Cancer (2003) (0)
Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanoma (2018) (0)
Abstract 2941: Functional proteomic aberrations post-chemotherapy with paclitaxel and carboplatin in patients with advanced ovarian cancer (2020) (0)
Abstract A47: DNA-PKcs is amplified in high-grade serous ovarian cancer (HGSC), correlates with poor outcome and drives resistance to platinum therapy via the AKT signaling pathway (2015) (0)
Abstract NG14: Proteome instability is an immunogenic therapeutic vulnerability in mismatch repair deficient cancer (2020) (0)
Abstract PR11: Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear-cell ovarian cancers (2020) (0)
AKT isoform-specific expression and activation across cancer lineages (2018) (0)
P3-14-09: A Phase II Preoperative Study of Dasatinib, a Multi-Targeted Tyrosine Kinase Inhibitor, in Locally Advanced “Triple-Negative” Breast Cancer Patients. (2011) (0)
A Bayesian hierarchical model for inference across related reverse phase protein arrays experiments (2014) (0)
Molecular determinants of post-mastectomy breast cancer recurrence (2018) (0)
A REVERSE PHASE ARRAY PLATFORM FOR MEASUREMENT OF PANCREATIC BIOMARKERS (2006) (0)
PDK1 as a preferred target for sensitizing breast cancer cells to gemcitabine (2004) (0)
Systems-based analysis of responses to stimulation or inhibition of EGF receptor signaling in breast cancer cells (2007) (0)
Abstract 4138: Five prognostic subgroups differ in expression of Akt pathway genes: Biomarkers for therapy selection (2011) (0)
Derived Stromal Cells − Pathway Induced in Leukemic Cells by Bone Marrow Activation of Integrin-Linked Kinase Is a Critical Prosurvival (2007) (0)
591 POSTER Overexpression of IKKβ is correlated with cytoplasmic expression of p21CIP1/WAF1 in human breast cancers (2006) (0)
Alkoxymethylenephosphonate Analogues of (Lyso)phosphatidic Acid Stimulate Signaling Networks Coupled to the LPA2 Receptor (2008) (0)
DL1-1: Adaptive Resistance to Targeted Therapies. (2011) (0)
Activating PIK3CA and AKT mutations in triple-receptor-negative breast cancer (2007) (0)
Resource Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer Graphical (0)
Abstract B106: Personalized functional screens for gene drivers of pancreatic cancer (2015) (0)
Abstract A10: Peroxiredoxin-1 and oxidative stress: Controlling the balance between oncogenic and endocrine signalling in estrogen receptor-positive breast cancer (2012) (0)
Synergistic effects of multi-level targeting of the MAPK and PI3-kinase pathways in breast cancer cells. (2007) (0)
Erratum: Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo (2017) (0)
Integration of specific copy number imbalances and prediction models of early-stage breast cancer recurrence. (2010) (0)
Erratum: Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo (2017) (0)
Use of next-generation sequencing (NGS) panels to predict recurrence in low-grade, early-stage endometrioid endometrial carcinoma. (2016) (0)
Role of membrane potential in the regulation of T-cell activation (1985) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
CD9 Contributes to Exit From Stem Cell-Like and Embryonic Diapause States and Transit to Drug Resistant States (2022) (0)
Abstract PD3-6: ConvertHER: Evolution of genomic alterations from primary to metastatic breast cancer (2015) (0)
Abstract OT-16-01: A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive (HR+) HER2 negative (HER2-) breast cancer (2021) (0)
Abstract LB-278: Metabolic regulator PGC-1α promotes angiogenesis and metastasis in nutrient deprivation selected tumor cells. (2013) (0)
Polymorphisms in the SULF 1 gene are associated with early age of onset and survival of ovarian cancer (0)
Downregulation of sIgM by recombinant interferon and phorbol esters (1986) (0)
Abstract PR09: Cellular heterogeneity of ovarian carcinoma cells and its impact on tumor behavior (2013) (0)
Abstract PR7: Visualizing the dynamic and heterogeneous responses of single cells to inhibitors of the growth factor signaling network (2012) (0)
Integration of functional proteomics with discrete non-parametric token-based modeling to identify combinational therapies targeting EGFR homeostatic loops in breast cancer cells (2007) (0)
326 Therapeutic targeting of AKT/ILK signaling in AML (2004) (0)
Implementing a comprehensive translational oncology platform: from molecular testing to actionability (2018) (0)
Protein Expression Signatures Determined by Reverse Phase Proteins Arrays (RPPA) Accurately Predict FLT3-ITD Mutation Status in AML. (2007) (0)
Abstract P1-07-01: A pan-cancer perspective of functional proteomics provides novel information content for uncommon breast cancer subtypes (2017) (0)
Phosphorylation of the IL2 receptor involves an inducible protein kinase (1985) (0)
Genetic Predisposition to Breast Cancer (2001) (0)
Abstract 668: Induction of mammary carcinoma in tetracycline-inducible cMET(T1010I) transgenic mice (2016) (0)
Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy (2019) (0)
The role of GSK3β in rapamycin-mediated cell cycle regulation (2005) (0)
Functional proteomic-based predictor of pathologic complete response to neoadjuvant chemotherapy with paclitaxel/FAC-FEC in breast cancer (2008) (0)
Caspase inhibitors and their use (2000) (0)
Abstract PR03: Single-cell proteomic analysis of the tumoral heterogeneity in response to PARP inhibitor (2020) (0)
Abstract 3271: The association between germline genetic variants in the PI3K-AKT-mTOR pathway and breast cancer disease free survival (2014) (0)
Abstract P5-06-08: Role of Androgen Receptor in Metastasis and Hormone Resistance of Estrogen Receptor Positive Breast Cancer (2010) (0)
Abstract 1656: Systematic identification of cancer therapeutic liabilities through adaptive functional proteomics (2019) (0)
Abstract PR03: Nongenomic BAP1 aberrancy drives highly aggressive cutaneous melanoma phenotype (2020) (0)
Abstract 4423: MiR551b-mediated Oncostatin M signaling in breast cancer (2018) (0)
Next-generation characterization of the Cancer Cell Line Encyclopedia (2019) (0)
Defining the role of non-canonical PIK3CA mutations in head and neck squamous cell carcinoma (2020) (0)
Abstract 3995: Identification of putative miRNA targets by a systems biological approach in NCI-60 data (2011) (0)
Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo (2017) (0)
Abstract 6278: Glutaminase inhibition in combination with ionizing radiation improves treatment response in head and neck squamous cell carcinoma models (2020) (0)
Overexpression of SnoN/SkiL, amplified at the locus, in ovarian cancers: A role in ovarian pathogenesis (2008) (0)
P4-05-03: Mechanism Underlying Metabolic Heterogeneity in Breast Cancer Subtypes. (2011) (0)
Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis. (2015) (0)
Abstract 4715: Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium (2015) (0)
Abstract 78: BRCA1/2 mutation analysis in 43 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation (2012) (0)
Advances in Brief MMAC 1 / PTEN Mutations in Primary Tumor Specimens and Tumor Cell Lines ' (2006) (0)
Abstract IA14: Functionalizing the cancer genome (2015) (0)
Resource Reveals Molecular Classification Multiplatform Analysis of 12 Cancer Types within and across Tissues of Origin (0)
0277: Proteomic Prediction in Epithelial Ovarian Cancer (2006) (0)
Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations. (2015) (0)
A high-depth multi-omics analysis of clinically defined subsets of high-grade serous ovarian cancer (2020) (0)
Combination Therapies Targeting the PI3K/AKT/mTOR Pathways (2016) (0)
Survivin is highly expressed in CD34 (cid:1) 38 (cid:2) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML (2012) (0)
Abstract 4451: Long-term resistance to PI3K/mTOR inhibition requires increased expression of c-myc and YAP. (2013) (0)
nucleosome-assembly-protein-l-related gene product involved in the induction of cell proliferation (2005) (0)
Abstract 5222: Identification of cell signaling pathway associated miRNAs in cancer cells using a systems biological approach. (2013) (0)
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome (2017) (0)
Proteomic Predictors of Outcome After Adjuvant Anti-Hormonal Therapy for Hormone Receptor-Positive Breast Cancer (2012) (0)
Corrigendum inference using steady-state data and Goldbeter-Koshland kinetics (2013) (0)
Comparison of Mutation Profile Among Responders and Non-Responders in a Cohort of Patients with Relapsed/Refractory Myeloid Malignancies Treated with MEK 1/2 Inhibitor Trametinib (2015) (0)
Companion Diagnostics and Cancer Biomarkers Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer (2014) (0)
Novel functional proteomics approach to defining ovarian cancer molecular heterogeneity (2007) (0)
Abstract P1-05-11: Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas (2017) (0)
Abstract 1540: Targeting PI3K/mTOR inhibitor induced survival programs abrogates resistance to cell death in ECM-attached cancer cells (2011) (0)
Abstract LB-217: A gene signature that predicts deficiency of homologous recombination DNA repair. (2013) (0)
Abstract 5139: An atlas of perturbed functional proteomics profiles of cancer cell lines (2020) (0)
Abstract 480: Biospecimen management for the serial measurement of molecular and architectural responses to therapy (2019) (0)
Abstract IA08: Functionalizing the cancer genome (2015) (0)
Casper: A phase I, open-label, dose finding study of calaspargase pegol-mnkl (cala) in combination with cobimetinib (cobi) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). (2023) (0)
Author response: Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression (2020) (0)
Induction of Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells (2001) (0)
Abstract 2346: ARDE: Detecting selectively expressed cancer driver mutations through integration of exome and transcriptome sequencing data (2018) (0)
TITLE : Experimental Analysis and Computational Modeling of Network States and Drug Responses in the PI 3 K / Akt / mTOR Network (2009) (0)
RNA editing derived epitopes function as cancer antigens to elicit immune responses (2018) (0)
Abstract A02: A novel orthotopic ovarian patient derived xenograft model platform to investigate novel therapies for BRCA deficient ovarian cancers (2016) (0)
A robust gene signature predicting deficient homologous recombination DNA repair (2013) (0)
Erratum: Effect of lysophospholipids on signaling in the human jurkat T cell line (Journal of Cellular Physiology (1995) 163 (441-450) DOI: 10.1002/jcp.1041630303) (2005) (0)
Characterization of patient-derived breast cancer xenografts demonstrates molecular evolution (2011) (0)
GENE-29. DEEP PANEL SEQUENCING OF A PROSPECTIVELY COLLECTED GLIOMA COHORT (2017) (0)
Aberrant vesicular trafficking contributes to altered polarity and metabolism in cancer (2013) (0)
Decoupling of the PI 3 K Pathway via Mutation Necessitates Combinatorial Treatment in HER 2 + Breast Cancer (2015) (0)
Patient-Derived Xenograft Models of Ovarian/Gynecologic Tumors (2017) (0)
Abstract 4033: Combined MEK and BCL-2/XLinhibition as a potential drug combination for the treatment of high-grade serous ovarian cancer (2017) (0)
Abstract LB-35: Site specific activation of AKT protects cells from death induced by glucose deprivation . (2013) (0)
Abstract A23: Bioinformatic analysis of PTPRK reveals a potential link to STAT3 phosphorylation in HNSCC. (2013) (0)
Abstract 2381: Loss of S6K2 perturbs redox balance and fatty acid metabolism, leading to oxidative cell death (2018) (0)
cells and predicts poor clinical outcomes in AML leukemic stem/progenitor - 38 + Survivin is highly expressed in CD34 (2013) (0)
Deficiency Overcoming Trastuzumab Resistance Caused by PTEN Preclinical Testing of Clinically Applicable Strategies for Updated (2007) (0)
Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. (2014) (0)
Abstract A037: YB-1 transforms mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer (2013) (0)
Extracellular lactate cooperates with limited glucose and glutamine to sustain breast cancer cell survival by providing ATP, NADPH, amino acids, and glutathione (2014) (0)
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies (2018) (0)
Abstract IA22: Systems approach to rational combination therapy (2020) (0)
P4-09-09: Expression of c-MET and Phospho c-MET in Breast Cancers by Subtype and Its Impact on Survival Outcomes. (2011) (0)
ivation of Murine Double Minute 2 by Akt in Mammary helium Delays Mammary Involution and R elerates Mammary Tumorigenesis (2010) (0)
Inhibition of the phosphatidylinositol 3’-kinase (PI3K) signaling pathway selectively enhances paclitaxel-induced apoptosis by modulating AKT and BAD phosphorylation in ovarian cancer cells (2004) (0)
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models (2019) (0)
Abstract 3459: A new promising drug through abating endoplasmic reticulum stress response in treating endometrial cancer (2015) (0)
Abstract PR05: Investigating the importance of low allele frequency mutations for cancer patient management (2015) (0)
Abstract B22: Establishment of Patient-Derived Xenograft (PDX) Models of Ovarian Cancer (2016) (0)
Breast cancer, bone metastasis, non-bone metastasis, copy number imbalances, molecular inversion probe array (2013) (0)
IN THE SPOTLIGHT Large-Scale Drug Screens Support Precision Medicine (2017) (0)
ComprehensiveGenomicAnalysis Identi fi esNovel Subtypes and Targets of Triple-Negative Breast Cancer (2015) (0)
Abstract 5478: The TRPA1 Ca2+-permeable channel mediates a non-canonical redox adaptation in cancer cells (2017) (0)
992TiPN-DUR: Matched pair pharmacodynamics study of neoadjuvant durvalumab in combination with chemotherapy in frontline ovarian cancer (2017) (0)
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes (2016) (0)
P4-05-01: Rab25 Alters Cellular Energetics and Growth Signaling during Breast Oncogenesis. (2011) (0)
Critical Questions in Ovarian Cancer Research and Treatment: Report of an AACR Special Conference (2019) (0)
Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. (2009) (0)
Targeting uncoupling of copy number and gene expression in cancers (2020) (0)
Towards a Unified Approach to New Target Discovery in Breast Cancer: Combining the Power of Genomics, Proteomics and Immunology (2006) (0)
Abstract 3688: Akt pathway genes classify GBM into 6 prognostic subgroups with different clinical and molecular features (2012) (0)
Use of submitogenic concentrations of phytohemagglutinin to dissect the requirements for induction of cell proliferation (1985) (0)
Abstract 4265: Derivation and characterization of endometrial cancer cells resistant to phosphatidylinositol-3-kinase (PI3K) pathway inhibitors. (2013) (0)
In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer (2018) (0)
Development of a Robust Protein Classifier to Predict EMT Status of Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC) Tumors (2015) (0)
Abstract 1353: The clinical utility of ctDNA in colorectal cancer validated by multiregional sequencing and protein analysis (2019) (0)
Predicting High-Risk Endometrioid Endometrial Carcinomas Using Protein Biomarkers (2017) (0)
Small Molecule Inhibitors of HER2 Inhibit Proliferative Signaling and Promote Apoptosis in Ph+ ALL (2011) (0)
Molecular Cancer apeutics linical Development amycin Regulates Stearoyl CoA Desaturase 1 Ther ression in Breast Cancer (2010) (0)
Use of gene expression patterns post neoadjuvant chemotherapy to identify a role for the MAPK phosphatase DUSP4 in therapeutic resistance and a stem-like phenotype in basal-like breast cancer (BLBC). (2011) (0)
Abstract 1099: High-throughput engineering and functional annotation of cancer fusion genes (2015) (0)
Integrated genomic characterization of oesophageal carcinoma (2017) (0)
Systematic Functional Ann otation of Somatic Mutations in Cancer Graphical (2018) (0)
Abstract P3-10-23: Caveolin 1 and Patient Outcomes in Breast Cancer (2010) (0)
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm (2017) (0)
Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer (2018) (0)
Abstract 2510: High-depth whole genome sequencing of clinically-annotated high-grade serous ovarian cancers (2020) (0)
A novel tumor suppressor gene ARHI induces autophagy in ovarian cancer (2006) (0)
Abstract IA11: Functionalization the cancer genome (2012) (0)
A-toI RNA Editing Contrib utes to Proteomic Diversity in Cancer Graphical (2018) (0)
Expression of Concern: Mechanisms underlying p53 regulation of <italic>PIK3CA</italic> transcription in ovarian surface epithelium and in ovarian cancer (2020) (0)
Abstract 3766: Identifying rational combination therapies with rapamycin for the treatment of epithelial cancers (2015) (0)
Genomic and proteomic approaches identify Rab25 as a potential prognostic marker for luminal B breast tumors (2010) (0)
Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery (2018) (0)
Activation of phosphatidylinositol 3-kinase (PI3K) as a predictor of clinical outcome in breast cancer patients (2001) (0)
Cell Reports Resource The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (0)
Enriched expression of PD-L1 and other immune targets after epithelial-mesenchymal transition (EMT) in squamous head and neck and lung cancers. (2015) (0)
Abstract B84: The association between germline genetic variants in the PI3K pathway and PI3K mutations in breast tumors. (2012) (0)
Prognosis Tumor Epidermal Growth Factor Receptor and EGFRPY 1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma (2012) (0)
Molecular therapeutics and pharmocogenomics (2003) (0)
Abstract 1273: Metabolic networks and the role of LDHB in breast cancer (2011) (0)
Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types (2016) (0)
The Role of the Rab Coupling Protein in ErbB2-Driven Mammary Tumorigenesis and Metastasis (2014) (0)
A systems approach to implementation of personalized cancer therapy (2017) (0)
Emerging genomic technology in cancer research: Its application in discovering and developing new therapeutic agents (2004) (0)
Abstract 392: Combined targeting of MET and PI3K improves efficacy in breast cancer models with concurrent MET/PI3K aberrations (2016) (0)
Mitogenic Cytokines Promote Apoptosis (1997) (0)
Stapled peptide inhibitors of RAB25 target context-specific phenotypes in cancer (2017) (0)
Immuno-genomic landscape of osteosarcoma (2020) (0)
Development of a public knowledgebase to facilitate decision support for clinical cancer genomics reporting and clinical trial enrollment. (2015) (0)

This paper list is powered by the following services:

Other Resources About Gordon B. Mills

en.wikipedia.org

Gordon B. Mills

Gordon B. Mills's Academic­Influence.com Rankings

Why Is Gordon B. Mills Influential?

Gordon B. Mills's Published Works

Published Works

Other Resources About Gordon B. Mills

What Schools Are Affiliated With Gordon B. Mills?

Gordon B. Mills's AcademicInfluence.com Rankings